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ABSTRACT 
 
Cellular and developmental processes are regulated by extracellular and 
intracellular signals that are mediated by networks of signaling pathways. In recent years, 
microRNAs have also emerged as a class of critical modulators of the same processes. 
For my thesis studies, I focused on regulatory mechanisms underlying mammalian cell 
survival and differentiation. In particular, I investigated the regulation of mammalian 
target of rapamycin  (mTOR), an evolutionarily conserved Ser/Thr kinase that integrates 
signals from nutrient availability, growth factors, differentiation inducers, and various 
types of stress, to control a wide range of biological processes. Separately, I also 
discovered a novel microRNA regulator of myogenic differentiation, microRNA-146b. 
Emerging evidence implicates the deregulation of mTOR signaling in a variety of 
diseases including cancer and diabetes, underscoring the importance to fully understand 
the regulation of mTOR signaling. mTOR forms two distinct complexes known as 
mTORC1 and mTORC2. mTORC2 controls a wide range of cellular functions, but the 
regulation of its signaling remains incompletely understood. In Chapter 2, I identified 
XPLN, a RhoGEF, as an endogenous inhibitor of mTORC2 kinase activity towards Akt. 
Furthermore, I showed that the GEF activity of XPLN is dispensable for its regulation of 
mTORC2 and Akt, whereas an N-terminal 125-amino acid fragment of XPLN is both 
necessary and sufficient for the inhibition of mTORC2. XPLN negatively regulates 
myoblast differentiation and cell survival by suppressing mTORC2 and Akt, and could 
likely be an important player in many other aspects of biology and diseases involving 
mTORC2 and Akt.  
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Next, I set out to search for a mechanism by which XPLN could be regulated in 
cells in order to allow Akt activation following growth factor stimulation. In Chapter 3, I 
investigated the subcellular localization of XPLN, and found it to be localized throughout 
the cell but concentrated in the nucleus. I subsequently manipulated the location by 
tagging various localization signals to XPLN and examined the functional consequence.  
Furthermore, I studied the function and localization of alternative splice isoforms of 
XPLN. 
Given the well-known hyperactivation of Akt in many human tumors, I probed a 
potential role of XPLN in cancer by analyzing its protein levels in various cancer cell 
lines, as described in Appendix A. Knockdown and overexpressed XPLN were also 
performed in cancer cells to probe the effects on Akt phosphorylation. Finally, as 
described in Appendix B, I am in the process of generating XPLN knockout mice using 
the TALEN technology, in order to facilitate future in vivo studies of XPLN.  
In Chapter 4, I identified and characterized microRNA-146b (miR-146b) as a 
novel positive regulator of skeletal myogenesis. Inhibition of miR-146b led to reduced 
myoblast differentiation, whereas overexpression of miR-146b enhanced differentiation. 
In addition, miR-146b directly targets Smad4, Hmga2, and Notch1 in muscle cells. The 
expression of miR-146b and its target genes was inversely correlated during myoblast 
differentiation and muscle regeneration, suggesting that these genes most likely mediate 
the myogenic function of miR-146b. 
In conclusion, my studies have uncovered novel regulators and mechanisms of 
mammalian cell survival and myogenic differentiation, and laid the foundation for future 
investigations. 
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CHAPTER 1. INTRODUCTION 
 
1.1. Mammalian (Mechanistic) Target of Rapamycin (mTOR) 
mTOR is an evolutionarily conserved Ser/Thr kinase that integrates signals from 
nutrient availability, growth factors, differentiation inducers, and various types of stress, 
to control a wide range of cellular and developmental processes (Laplante and Sabatini, 
2009b). Emerging evidence indicates the deregulation of mTOR signaling in a variety of 
diseases including cancer and diabetes (Zoncu et al., 2011), underscoring the importance 
to fully understand the regulation of mTOR signaling.  
mTOR was first identified in the budding yeast Saccharomyces cerevisiae as a 
specific target of Rapamycin (Heitman et al., 1991). Rapamycin is a bacterial macrolide 
that has demonstrated enormous clinical value as a three-time FDA approved drug: an 
immunosuppressant (Abraham and Wiederrecht, 1996), an anti-restenosis drug in 
angioplastic stenting (Serruys et al., 2002), and an anti-cancer drug (Hidalgo and 
Rowinsky, 2000; Vogt, 2001). Rapamycin forms a complex with the ubiquitous cellular 
protein FKBP12, which then binds to the FRB (FKBP12-rapamycin binding) domain and 
inhibits TOR functions. Four years after the discovery of yeast TOR, cloning of mTOR 
was reported independently by two groups at the same time and named as FRAP (FK506-
binding protein 12 (FKBP12), rapamycin-associated protein) (Brown et al., 1994), 
RAFT1 (rapamycin and FKBP12 target-1) (Sabatini et al., 1994), in addition to mTOR 
(Sabers et al., 1995). 
As shown in Fig. 1.1, mTOR nucleates two distinct multi-protein complexes 
known as mTOR Complex 1 (mTORC1) and mTOR Complex 2 (mTORC2) (Foster and 
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Fingar, 2010). mTORC1 consists of the defining subunit rapamycin-sensitive adaptor 
protein of mTOR (raptor). Besides raptor and mTOR, mTORC1 also includes negative 
regulators 40 kDa Prorich Akt substrate (PRAS40) and DEP domain-containing mTOR-
interacting protein (Deptor), as well as a positive regulator mammalian lethal with SEC13 
protein 8 (mLST8), also known as G protein β-subunit-like protein (GβL) (Kim et al., 
2003) in addition to mTOR. mTORC1 regulates cell growth and proliferation by 
promoting biosynthesis of proteins, lipids, and organelles while inhibiting autophagy 
(Laplante and Sabatini, 2009a). The best characterized substrates for the mTORC1 kinase 
are S6 Kinase 1 (S6K1) and eIF-4E-Binding Protein-1 (4E-BP1), both key regulators of 
protein synthesis (Ma and Blenis, 2009).  
  The TSC1/TSC2 complex has emerged as a critical regulator of mTORC1 
signaling in cell growth by serving as a hub for receiving multiple upstream signals 
(Marygold and Leevers, 2002; McManus and Alessi, 2002), including mitogenic 
stimulation, cellular energy deprivation, hypoxia, inflammatory signals, and oncogenic 
Wnt signaling (Erbay et al., 2005; Guertin and Sabatini, 2007; Hay and Sonenberg, 2004; 
Inoki et al., 2006; Lee et al., 2007; Wullschleger et al., 2006). The TSC1/2 complex 
inhibits mTORC1 by inactivating the small GTPase Rheb through a GTPase-activating 
protein (GAP) activity in TSC2. 
mTORC2 is defined by the subunits rapamycin-insensitive companion of mTOR 
(rictor), positive regulators protein observed with rictor (Protor), and mammalian stress-
activated map kinase-interacting protein 1 (mSIN1). It also shares mTOR, Deptor and 
mLST8 with mTORC1 (Foster and Fingar, 2010). mTORC2 phosphorylates the 
hydrophobic motif site Ser473 on Akt that is necessary for its activation (Sarbassov et al., 
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2005), as well as the turn motif controlling the folding and stability of Akt (Facchinetti et 
al., 2008; Ikenoue et al., 2008). Thus, mTORC2 is involved in a variety of processes that 
are regulated by Akt, including cell survival, glucose metabolism, and cellular 
differentiation (Ge and Chen, 2012; Manning and Cantley, 2007). In addition, mTORC2 
regulates cytoskeleton organization by promoting phosphorylation of protein Kinase C 
(PKCα) (Facchinetti et al., 2008; Ikenoue et al., 2008; Jacinto et al., 2004; Sarbassov et 
al., 2004). More recently, serum/glucocorticoid regulated kinase 1 (SGK1) has also been 
identified as a substrate of mTORC2 (Hong et al., 2008).  
In contrast to mTORC1, for which mechanisms of activation by upstream signals 
have been extensively studied, relatively little is known about the regulation of mTORC2 
signaling. PI3K activity and TSC1/2 have been reported to mediate mitogenic stimulation 
of mTORC2 kinase activity (Huang et al., 2008). Growth factor receptors activate 
mTORC2 near the plasma membrane, where mTORC2 may be recruited through binding 
of mSIN1. While PRAS40 and FKBP38 both specifically inhibit mTORC1, DEPTOR 
interacts with mTOR to negatively regulate both mTORC1 and mTORC2 (Foster and 
Fingar, 2010; Laplante and Sabatini, 2009a).  
 
1.2. Akt/Protein Kinase B (PKB) 
Akt/PKB is a member of the AGC kinase family that includes S6K, SGK, and 
PKC. Akt is a serine/threonine kinase that was originally implicated in cancer 
development, cell proliferation and inhibition of apoptosis (Datta et al., 1999). Mammals 
have three known isoforms - Akt1, Akt2, and Akt3, all having the same general structure 
consisting of an N-terminal PH domain, known to target Akt to the plasma membrane, 
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and a C-terminal kinase domain. Akt1 and Akt2 are widely distributed in all the tissues 
whereas Akt3 is predominantly restricted to the nervous system and testis. Knockdown 
and knockout studies have shown that different isoforms of Akt are involved in distinct 
biological processes (Gonzalez and McGraw, 2009). Akt1 is majorly implicated in cell 
growth and lifespan (Chen et al., 2001), while Akt2 is involved in glucose homeostasis 
by regulating glucose utilization and hepatic glucose output (Cho et al., 2001). Akt3 has a 
significant role in neural development (Tschopp et al., 2005).  
Akt plays a central role in controlling cell growth, proliferation, survival, and 
differentiation by phosphorylating a diverse number of protein substrates. Most of the 
substrates of Akt contain a minimal consensus sequence RXRXXS/T (Scheid and 
Woodgett, 2001). Akt substrates implicated in metabolism, cell growth, and proliferation 
are GSK3, mTOR, and TSC2. Glycogen synthase kinase 3 (GSK3) was identified as the 
first physiological target of Akt (Cross et al., 1995). Akt phosphorylates and inactivates 
GSK3 preventing it from phosphorylating glycogen synthase. Therefore, inactivation of 
GSK3 by Akt results in dephosphorylation of glycogen synthase and hence the activation 
of glycogen synthesis (Frame and Cohen, 2001). Akt has also been well characterized as 
a major pro-survival molecule, through regulation of apoptosis by phosphorylation of 
BAD, ASK1, and FoxO proteins (Lawlor and Alessi, 2001).  
Akt activation is a highly regulated multistep process that involves both 
membrane translocation and phosphorylation. Upon activation by membrane-bound 
receptors, such as receptor tyrosine kinases (RTKs) PI3K generates PI-3,4-P2 and PI-
3,4,5-P3 at the plasma membrane. Both phospholipids bind with high affinity to the PH 
domain, mediating membrane translocation of Akt. Once situated at the membrane, Akt 
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is phosphorylated at two sites. First is threonine (Thr) 308 in Akt1 (309 in Akt2 and 305 
in Akt3) in the activation loop or T-loop, by PH domain‐containing AGC kinase, PDK1. 
Second is serine (Ser) 473 (474 in Akt2 and 472 in Akt3) in the hydrophobic motif of the 
C‐terminal tail by mTORC2 (Sarbassov et al., 2005). Whereas T‐loop phosphorylation is 
absolutely required for Akt activation, the C‐terminal phosphorylation potentiates Akt 
activity by promoting a conformational change in the T‐loop (Yang et al., 2006). 
Although mTORC2 is the major kinase for Ser 473 phosphorylation, other candidates 
include the integrin‐linked kinase (ILK) (Persad et al., 2001), mitogen‐activated protein 
kinase‐activated kinase 2 (MAPKAPK2), Ataxia telangiectasia mutated (ATM) kinase 
and Akt itself. These kinases have been proposed to phosphorylate in various cell 
contexts (Liao and Hung, 2010). Very recently, a direct link between cell cycle and Akt 
activation was revealed through identification of cyclin-dependent-kinase2 (cdk2)/cyclin 
A2 as a physiological kinase for Akt at amino acid residues S477 and T479 in the 
extreme C terminus of Akt (Liu et al., 2014). Similar to S473 regulation, it was shown 
that S477/T479 phosphorylation can be mediated by cdk2, DNAPK, or mTORC2 
depending on the particular cell context.  
There are a couple of known negative regulators of Akt signaling. The PI3K/Akt 
axis is directly antagonized by the 3′‐lipid phosphatase activity of the phosphatase PTEN, 
which removes the 3′‐phosphate of PI3K products, leading to abrogation of PI3K 
signaling (Di Cristofano and Pandolfi, 2000). Another negative regulator is a Ser/Thr 
phosphatase called PHLLP (PH domain leucine-rich repeat protein phosphatase).  
PHLLP removes the hydrophobic motif phosphorylation (Ser473 phosphate of Akt1) to 
dampen Akt signaling (Gao et al., 2005). In addition, several other serine‐threonine 
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phosphatases, including protein phosphatase 2A, are proposed to be involved in the 
inactivation of Akt.  
Akt is one of the most frequently activated kinases in cancer (Bellacosa et al., 
2005; Hay, 2005; Khan et al., 2013; Manning and Cantley, 2007; Morgensztern and 
McLeod, 2005; Zoncu et al., 2011). Over-expression and amplification of Akt2 was first 
reported in 1992 and is now frequently seen in prostate and ovarian carcinomas 
(Altomare and Testa, 2005). Akt2 overexpression is linked to the malignant phenotype 
leading to generation of hyper responsive cells that are overly sensitive to normal growth 
factors. Unlike Akt2, Akt1 and Akt3 are not commonly overexpressed in cancer. Instead, 
mutations and genomic deletions of the upstream regulators of Akt lead to hyperactivated 
Akt signaling and resistance to apoptosis. 
Various mechanisms contribute to Akt hyperactivation in cancer. Most commonly 
occurring germ line modifications are activating mutations in or overexpression of PI3K, 
inactivating mutations in or deletion of PTEN, and amplification or overexpression of 
receptor tyrosine kinases such as EGFR and Her2 (Yuan and Cantley, 2008).  
 
1.3. Skeletal Myogenesis 
Skeletal myogenesis occurs both during embryonic development and adulthood. 
During embryonic development, mesodermal cells undergo myogenic commitment 
forming proliferating myoblasts, which differentiate terminally and fuse to give rise to 
nascent myofibers, characterized as the first stage of skeletal myogenesis. These nascent 
myofibers continue to fuse to form mature myofibers during the next stage (Parker et al., 
2003a). Adult skeletal muscle generates force in a controlled and directed manner 
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through contraction of these highly specialized multinucleated myofibers (Wagers and 
Conboy, 2005). Its life-long action relies on maintenance and regeneration of myofibers. 
Muscle repair is carried out by a population of stem cells called satellite cells present 
between plasma membrane and surrounding basal lamina of mature muscle fibers 
(Wagers and Conboy, 2005). Following injury, mitotically quiescent satellite cells re-
enter cell cycle, divide and ultimately fuse with existing myofibers or with each other to 
promote repair and regeneration (Sabourin and Rudnicki, 2000).  
Embryonic myogenesis is believed to share regulatory mechanisms with adult 
muscle regeneration, especially at myoblast differentiation stages. Muscle progenitor 
cells in the somites express Pax3 allowing proliferation while simultaneously preventing 
precocious differentiation. To initiate myogenesis, these mesodermal cells migrate to 
limb buds and initiate Pax7 expression. Paired-domain transcription factors Pax3 and 
Pax7 act upstream of the primary myogenic basic helix–loop–helix (bHLH) transcription 
factors Myf5 and MyoD in allowing myogenic specification. Following downregulation 
of Pax3/7, these cells proliferate as myoblasts and then differentiate after activation of 
Myogenin, another myogenic regulatory gene of the MyoD family. Myogenin expression 
is followed by p21 induction marking cell cycle withdrawal and phenotypic 
differentiation as marked by MHC expression. These myoblasts then undergo initial cell 
fusion to form nascent myofibers followed by second-stage fusion to form mature 
myofibers (Parker et al., 2003b).  
The C2C12 murine myoblast cell line serves as a commonly used model that 
recapitulates myoblast differentiation in vitro, and provides a powerful system. When 
kept subconfluent, these cells proliferate continuously in the presence of growth factors. 
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Upon growth factor deprivation, they exit cell cycle and fuse to form multi-nucleated 
myotubes expressing muscle-specific genes (Yaffe and Saxel, 1977).  
 
1.4. mTOR Signaling in Myogenesis 
In addition to regulating various aspects of skeletal muscle physiology including 
metabolic homeostasis, muscle hypertrophy and atrophy (Glass, 2003), mTOR is a master 
regulator of myogenesis, and it regulates distinct stages of myogenesis by assembling 
different pathways (Ge and Chen, 2012). As shown in Fig. 1.2, at the initiation stage, 
mTOR controls the transcription of IGF-II through a muscle-specific enhancer in a 
kinase-independent manner (Erbay and Chen, 2001; Erbay et al., 2003). On the other 
hand, the catalytic activity of mTOR is required for a second-stage fusion that results in 
formation of mature myotubes (Park and Chen, 2005).  
 The insulin-like growth factors (IGF-I and IGF-II) are critically involved in 
skeletal muscle development as well as adult muscle regeneration (Barton-Davis et al., 
1998; Florini et al., 1991a; Musaro et al., 2001). In various myoblast cultures the 
autocrine/paracrine actions of IGFs, induced in response to growth factor deprivation, are 
instrumental in the initiation of differentiation (Florini et al., 1991b; Musaro and 
Rosenthal, 1999; Tollefsen et al., 1989a; Tollefsen et al., 1989b). Pharmacological and 
genetic evidence has indicated the PI3K/Akt pathway as a major mediator of myogenic 
signaling downstream of IGFs (Jiang et al., 1999; Jiang et al., 1998; Kaliman et al., 1998; 
Kaliman et al., 1996).  
FoxO1 (Forkhead box protein O1) is the major downstream target of Akt 
signaling known to suppress myogenic differentiation (Hribal et al., 2003). The FoxO 
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proteins are key regulators of a wide range of cellular functions, such as proliferation, 
survival, differentiation, and metabolism (Accili and Arden, 2004; Barthel et al., 2005). 
Many signaling pathways converge on FoxO, but inactivation by Akt phosphorylation 
appears to be a prevalent mechanism in a variety of cellular contexts (Tran et al., 2003). 
 
1.5. MicroRNAs 
MicroRNAs are a class of small non-coding RNAs that have emerged as 
important regulators of gene expression (Bartel, 2009).There are >3000 miRNAs in 
humans (miRBase.org) and they are predicted to target ~30-60% genes in the human 
genome. They are important in regulating cellular and developmental processes as 
diverse as embryonic development, cell proliferation, cell growth, tissue differentiation, 
and apoptosis (Felekkis et al.; Stefani and Slack, 2008).  
Mature microRNAs are derived from longer transcripts (named pri-miRNA) 
transcribed by RNA Polymerase II (Lee and Dutta, 2009), either as independent 
transcriptional units or as parts of introns of protein coding genes. These pri-miRNAs are 
processed by nuclear RNaseIII-type endonuclease Drosha along with DGCR8 (Gregory 
et al., 2004; Han et al., 2006), also called microprocessor complex, to generate ~70 
nucleotide pre-miRNAs containing a stem-loop structure. A subset of miRNA called 
miRtrons bypass the Drosha processing through an alternative pathway, where they are 
produced during gene splicing (Ruby et al., 2007). These pre-miRNAs are then exported 
to the cytoplasm by Exportin-5 in a Ran-GTP dependent manner (Yi et al., 2003) where 
they are further processed by Dicer, another RNaseIII-type endonuclease, in complex 
with TRBP, to yield ~22 nucleotide mature miRNA duplexes (Hutvagner et al., 2001). 
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Adequate levels of both components of Microprocessor (Drosha and DGCR8) are 
ensured by a positive–negative feedback loop. DGCR8 stabilizes Drosha and Drosha 
downregulates the DGCR8 mRNA by targeting two hairpin structures in the 5′UTR and 
coding sequence of DGCR8 that resemble those found in pri-miRs (Han et al., 2009).  
One strand of these duplexes is then selected for incorporation into RNA induced 
Silencing Complexes (RISC) composed of proteins of Argonaute family and other 
accessory factors along with the target mRNA (Filipowicz et al., 2008). The target 
mRNA is subsequently translationally repressed and often decayed as well (Filipowicz et 
al., 2008; Wu et al., 2006).  
MicroRNAs bind to their target mRNAs through partial complementarity. 
Rigorous bioinformatic analysis of miRNA-regulated genes showed that pairing of 
miRNA nucleotides 2–8, called the seed region, to the 3′ untranslated region (UTR) of 
the target mRNA is often important. Other factors that play an important role in 
predicting targets are evolutionary conservation of the MRE (miRNA recognition 
element), free energy of the miRNA-mRNA heteroduplex, and mRNA sequence features 
outside the target site (Thomas et al., 2010).  
 
1.6. MicroRNAs in Skeletal Myogenesis 
Every aspect of skeletal myogenesis has been shown to be regulated by miRNA 
(Ge and Chen, 2011), with more myogenic miRNAs discovered continuously. The 
strongest evidence for the essential role of miRNAs in skeletal myogenesis came from 
the analysis of skeletal muscle-specific Dicer knockout mice, which have severely 
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reduced muscle mass along with abnormal myofiber morphology leading to death within 
minutes of birth (O'Rourke et al., 2007).  
Overexpression and knockdown experiments in myoblasts first revealed the 
myogenic roles of the highly conserved miR-1, miR-206 and miR-133 (Chen et al., 2006; 
Kim et al., 2006). Later, more miRNAs were recognized to regulate most known steps of 
skeletal myogenesis by targeting crucial regulators that regulate the process (Ge and 
Chen, 2011). Chapter 4 of my thesis will describe the identification and characterization 
of a novel miRNA, miR-146b, in regulating skeletal myogenesis.  
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1.7. Figures 
 
 
 
      
 
Fig. 1.1. mTOR complexes. Two biochemically distinct mTOR complexes that have 
distinct and shared regulators, and substrates that mediate specific functions. 
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Fig. 1.2. Rapamycin-sensitive mTOR signaling controls distinct stages of skeletal 
myogenesis. Formation of nascent myotubes is regulated by mTOR in a kinase-
independent manner, whereas maturation of myotubes/myofibers requires mTOR kinase 
activity. Borrowed from (Ge and Chen, 2012). 
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CHAPTER 2. XPLN IS AN ENDOGENOUS INHIBITOR OF mTORC2 1 
 
2.1. Introduction 
Mammalian Target of Rapamycin  (mTOR) is an evolutionarily conserved 
Ser/Thr kinase that integrates signals from nutrient availability, growth factors, 
differentiation inducers, and various types of stress, to control a wide range of cellular 
and developmental processes (Foster and Fingar, 2010; Zoncu et al., 2011). mTOR 
nucleates two distinct multi-protein complexes known as mTOR Complex 1 (mTORC1) 
and mTOR Complex 2 (mTORC2), characterized by the presence of raptor and rictor, 
respectively. Emerging evidence implicates the deregulation of mTOR signaling in a 
variety of diseases including cancer and diabetes (Zoncu et al., 2011), underscoring the 
importance to fully understand the regulation of mTOR signaling. 
mTORC1 regulates cell growth and proliferation by promoting biosynthesis of 
proteins, lipids, and organelles while inhibiting autophagy (Foster and Fingar, 2010; 
Zoncu et al., 2011). The best characterized substrates for the mTORC1 kinase are S6 
Kinase 1 (S6K1) and eIF-4E-Binding Protein-1 (4E-BP1), both key regulators of protein 
synthesis (Ma and Blenis, 2009). mTORC2 phosphorylates the hydrophobic motif site 
Ser473 on Akt that is necessary for its activation (Sarbassov et al., 2005), as well as the 
turn motif controlling the folding and stability of Akt (Facchinetti et al., 2008; Ikenoue et 
al., 2008). The ribosome plays a direct role in activating mTORC2 (Zinzalla et al., 2011), 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 All the data in this chapter except Fig. 2.11 appeared in PNAS as : 
Khanna N., et al, 2013. XPLN is endogenous inhibitor of mTORC2. Proc Natl Acad Sci 
U S A. 2013 Oct 1;110(40):15979-84. It is available from 
http://www.pnas.org/content/110/40/15979.long and using doi: 
10.1073/pnas.1310434110.  	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and association with the ribosome also allows mTORC2 to phosphorylate and stabilize 
Akt co-translationally (Oh et al., 2010). Thus, mTORC2 is involved in a variety of 
processes that are regulated by Akt, including cell survival, glucose metabolism, and 
cellular differentiation (Ge and Chen, 2012; Manning and Cantley, 2007; Oh and Jacinto, 
2011). In addition, mTORC2 regulates cytoskeleton organization by promoting 
phosphorylation of protein Kinase C (PKCα) (Facchinetti et al., 2008; Ikenoue et al., 
2008; Jacinto et al., 2004; Sarbassov et al., 2004), and serum/glucocorticoid regulated 
kinase 1 (SGK1) has also been identified as a substrate of mTORC2 (Garcia-Martinez 
and Alessi, 2008). Compared to mTORC1, for which mechanisms of activation by 
upstream signals have been extensively studied, less is known about the regulation of 
mTORC2 signaling. Several endogenous inhibitors of mTOR have been reported. While 
PRAS40 and FKBP38 are specific inhibitors of mTORC1, DEPTOR interacts with and 
inhibits both mTORC1 and mTORC2 (Foster and Fingar, 2010; Zoncu et al., 2011). 
Recently, the glucocorticoidinduced leucine zipper protein (GILZ) was reported to inhibit 
mTORC2 when overexpressed in BCR-ABL-expressing chronic myeloid leukemia 
(CML) cells (Joha et al., 2012).  
XPLN (eXchange factor found in platelets, leukemic, and neuronal tissues) is a 
RhoGEF (guanine exchange factor) selectively activating RhoA and RhoB in vitro 
(Arthur et al., 2002). Like most RhoGEFs, XPLN contains a Dbl homology (DH) domain 
followed by a pleckstrin homology (PH) domain. This protein is expressed in several 
human tissues, with the highest levels found in the skeletal muscle and brain (Arthur et 
al., 2002). As expected for a protein with RhoGEF activity in vitro, overexpression of 
recombinant XPLN stimulates Rho-kinase dependent assembly of stress fibers and focal 
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adhesion, and has cell transforming activity (Arthur et al., 2002). However, a biological 
function for the endogenous XPLN has not been reported. 
Here we identify XPLN as an mTORC2-interacting protein. We find that XPLN 
inhibits mTORC2 kinase activity in vitro and activation of Akt in cells. Interestingly, this 
function of XPLN is independent of its GEF activity and is most likely mediated by a 
physical interaction between its N-terminus and mTORC2. Furthermore, we show that 
XPLN negatively regulates cell survival and myoblast differentiation through inhibiting 
mTORC2 and Akt. These findings reveal XPLN as a novel regulator of mTORC2 
signaling to Akt via a non-canonical mechanism. 
 
2.2. Materials and Methods 
2.2.1. Antibodies and other reagents. Rabbit polyclonal antibody against XPLN was 
generated by Proteintech Group Inc. using peptide REPQGETKLEQMDQSDSE as the 
antigen, and affinity purified. Anti-MHC (MF20) and anti-myogenin (F5D) were from 
the Developmental Studies Hybridoma Bank developed under the auspices of the 
NICHD, National Institutes of Health, and maintained by The University of Iowa, 
Department of Biological Sciences. Anti-tubulin antibody was from Abcam, anti-Myc 
clone 9E10 from Covance, anti-Flag M2 from Sigma, anti-GST (B-14) from Santa Cruz, 
anti-pS657-PKC from upstate technology, anti-raptor and anti-rictor from Bethyl 
Laboratories. All other primary antibodies were from Cell Signaling Technology. All 
secondary antibodies were from Jackson ImmunoResearch Laboratories, Inc. Akt 
inhibitor (Akti-1/2) was from Calbiochem. Glutathione Sepharose was from GE 
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Healthcare. Protein G-agarose and His-Akt were from Millipore. All other reagents were 
from Sigma-Aldrich.  
2.2.2. Plasmids. pCMV6-myristoylated-HA-Akt (c.a.-Akt) was previously described 
(Erbay et al., 2003). pCMV-Myc-XPLN (human) and pGEX-4T-1-XPLN were generous 
gifts from Dr. Krister Wennerberg (University of Helsinki) (Arthur et al., 2002). Various 
fragments and mutants of XPLN cDNA were generated by PCR or site-directed 
mutagenesis (Mutagenesis Kit, Stratagene).  
2.2.3. Cell culture. HEK 293 and HeLa cells were maintained in DME containing 10% 
fetal bovine serum (FBS) at 37 °C with 5% CO2. All transient transfections in HEK293 
cells were performed with PolyFect (Qiagen) following manufacturer’s protocols at 60-
70% cell confluence. C2C12 myoblasts were maintained in DME containing 1 g/L 
glucose and 10% FBS at 37°C with 7.5% CO2. Transfection of C2C12 was performed 
using TransIT-LT1 (Mirus) following the manufacturer’s recommendations, followed by 
selection in 1.0 mg/ml G418 for 2-3 days. Primary myoblasts were isolated from 2- to 5-
day-old FVB neonates as described previously (Ge et al., 2011a), and maintained at low 
density on 1% gelatin-coated tissue culture plates. All animal experiments in this study 
followed protocols approved by the Animal Care and Use Committee at the University of 
Illinois at Urbana-Champaign. Lentiviral infection of C2C12 and primary myoblasts was 
performed as previously described (Yoon and Chen, 2008), with 3 mg/mL puromycin 
selection in C2C12 for 2 days and no drug selection for primary myoblasts.  
Myogenic differentiation of C2C12 cells and primary myoblasts were induced at 
100% and 50-70% confluence, respectively, by switching to DME containing 2% horse 
serum as previously described (Yoon and Chen, 2008). Differentiated cells in 12-well 
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plates were fixed, and stained for MHC and DAPI as previously described (Yoon and 
Chen, 2008). The stained cells were examined with a Leica DMI 4000B fluorescence 
microscope, and the fluorescent images were captured using a RETIGA EXi camera and 
analyzed with Q-capture Pro51 software (Q-ImagingTM). The fusion index was calculated 
as the percentage of nuclei in myocytes with ≥2 nuclei. Each data point was generated 
from scoring 5 randomly chosen microscopic fields. 
2.2.4. Lentivirus-mediated RNAi. Lentivirus packaging and infection were performed 
as previously described (Ge et al., 2011b). All shRNAs were from the MISSION® TRC 
library (Sigma-Aldrich). The shRNAs for mouse mTOR, Raptor, rictor, and negative 
control (scramble hairpin) have been reported (Ge et al., 2011b). XPLN shRNAs were 
from the MISSION® TRC library (Sigma-Aldrich). The clone IDs are: mouse XPLN #1, 
NM_027871.1-458s1c1; human XPLN #1, NM_019555.1-226s1c1; mouse and human 
XPLN #2, NM_019555.1-578s1c1. 
2.2.5. Western blotting, immunoprecipitation. Cells were lysed in ice-cold lysis buffer 
(40 mM HEPES, pH7.2, 120 mM NaCl, 10 mM pyrophosphate, 50 mM NaF, 10 mM b-
glycerophosphate, 2 mM EDTA, 1x Sigma protease inhibitor cocktail, and 0.3% 
CHAPS). The supernatant after microcentrifugation at 13,000 rpm for 10 min was 
collected and subjected to immunoprecipitation at 4oC with various antibodies in the lysis 
buffer, followed by incubation with Protein G-agarose. The beads were washed with lysis 
buffer, and then boiled in SDS sample buffer. Proteins were resolved on SDS-PAGE and 
transferred onto PVDF membrane (Millipore), followed by incubation with various 
antibodies according to the manufacturers’ recommendations. Detection of horseradish 
peroxidase-conjugated secondary antibodies was performed with Western LightningTM 
	   25	  
Chemiluminescence Reagent Plus (Perkin Elmer, Inc.). Quantification of Western band 
intensities was performed by densitometry of X-ray film images using the software  
Image J. 
2.2.6. Purification of GST-fusion proteins, GST pulldown assays. GST and GST-
XPLN were expressed in E. coli and purified using glutathione Sepharose beads (GE 
Healthcare) following the manufacturer’s recommendations. Purified proteins (20 µg 
each) were pre-incubated with cell lysates for 60 min before incubation with glutathione 
Sepharose for 90 min, followed by washing with lysis buffer. 
2.2.7. In-vitro mTOR kinase assays.  mTORC1 and mTORC2 were 
immunoprecipitated using anti-raptor and anti-rictor antibodies, respectively. The kinase 
assays were performed following procedures described by Ikenoue et al. (Ikenoue et al., 
2009). mTORC1 kinase assays were carried out at 30oC for 30 min in 25mM HEPES (pH 
7.4), 50 mM KCl, 10 mM MgCl2 and 250 µM ATP, with 100 ng GST-S6K1 4EBP1 as 
the substrate. mTORC2 kinase assays were carried out at 37oC for 30 min in 25mM 
HEPES (pH 7.4), 100 mM potassium acetate, 1 mM MgCl2 and 500 µM ATP, with 250 
ng His-Akt as the substrate. Where applicable, purified GST proteins (1 µg each) were 
added to the immunocomplexes 15 30 min before initiation of the kinase assay by the 
addition of ATP. Reactions were stopped by the addition of SDS sample buffer and 
boiling. 
2.2.8. RhoA activity assay. GTP-bound RhoA was measured following the method 
described by Ren and Schwartz (Ren and Schwartz, 2000). The amount of GTP-bound 
RhoA was measured using the method described by Ren and Schwartz (Ren and 
Schwartz, 2000). Briefly, cells were lysed in 50 mM Tris, pH 7.4, 10 mM MgCl2, 500 
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mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholate, and 1x Protease Inhibitor 
Cocktail. Cleared lysates were incubated with glutathione-Sepharose beads containing 30 
μg of GST-RBD (GST fusion to the Rho-binding domain of Rhotekin protein), and the 
beads were washed in 50 mM Tris, pH 7.4, 10 mM MgCl2, 150 mM NaCl, 1% Triton X-
100, and 1x Protease Inhibitor Cocktail. Bound proteins and lysates were analyzed by 
Western blotting with anti-RhoA antibody. 
2.2.9. Statistical analysis. All data are presented as mean ± SD, or representative blots, 
of at least 3 sets of independent experiments. Whenever necessary, statistical significance 
of the data was analyzed by performing one-sample or paired t tests. 
 
2.3. Results 
2.3.1. XPLN interacts with mTORC2. To explore novel interacting partners of mTOR, 
we carried out yeast two-hybrid screens using the C-terminal 1188 amino acids of mTOR 
(a.a. 1362-2549) as bait against a HeLa cell cDNA prey library. XPLN cDNA emerged as 
a positive hit and was confirmed in secondary assays in yeast.  The interaction between 
full-length mTOR and XPLN was then examined in mammalian cells. As shown in Fig. 
2.1A, Flag-mTOR stably expressed in HEK293 cells co-immunoprecipitated with 
transiently expressed Myc-XPLN, and vice versa. In addition, bacterially purified GST-
XPLN associated with endogenous mTOR in pull-down assays performed with both 
HEK293 (Fig. 2.1B) and mouse C2C12 cell lysates (Fig. 2.1C). Furthermore, GST-
XPLN associated with endogenous rictor, and not raptor (Fig. 2.1B & C), suggesting that 
the interaction may be specific for mTORC2. Indeed, both mSin1 and mLST8, the other 
components of mTORC2 (Oh and Jacinto, 2011), were found to associate with GST-
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XPLN (Fig. 2.1B), and immunoprecipitation of endogenous rictor and mSin1 brought 
down Myc-XPLN stably expressed in HEK293 cells (Fig. 2.1D).  
 The interaction between XPLN and mTOR complexes was further investigated in 
cells with lentivirus-delivered shRNA-mediated knockdown of mTOR, raptor, and rictor. 
Depletion of rictor significantly impaired the interaction between mTOR and XPLN, 
whereas removal of mTOR had no effect on rictor-XPLN interaction (Fig. 2.1E). On the 
other hand, raptor depletion slightly increased XPLN interaction with mTOR and rictor 
(Fig. 2.1E). Hence, the XPLN-mTOR interaction appears to be mediated by rictor, 
although we cannot rule out a possible involvement of mSin1, the presence of which is 
necessary for rictor association with mTOR (Oh and Jacinto, 2011). Our original two-
hybrid result could be explained by the presence of orthologs of mTORC2 components in 
yeast (Avo3 and Avo1) (Frias et al., 2006; Jacinto et al., 2006). Although the Avo3 (yeast 
rictor)-binding site (Wullschleger et al., 2005) is in a region of TOR2 absent in our two-
hybrid bait, the C-terminal 80 kDa of mTOR – included in the bait – binds rictor 
(Panasyuk et al., 2009) and thus may also bind Avo3. 
 
2.3.2. XPLN negatively regulates Akt phosphorylation and cell survival. XPLN has 
been reported to stimulate the assembly of focal adhesions and stress fibers in a Rho-
kinase dependent manner (Arthur et al., 2002). Since mTORC2 has been implicated in 
the regulation of actin cytoskeleton (Jacinto et al., 2004; Sarbassov et al., 2004), and in 
yeast TOR2 activates RHO1 and RHO2 through its GEF ROM2 (Schmidt et al., 1997), a 
plausible model would be that mTORC2 regulates GEF activity of XPLN towards RhoA 
proteins. However, knockdown of mTOR or rictor had no effect on RhoA-GTP levels in 
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HEK293 cells, as assayed by pull-down of active RhoA with GST-RBD (Rho-binding 
domain of Rhotekin) (Fig. 2.6). RhoB expression was not detected in these cells. 
Although this lack of mTORC2 effect on RhoA did not completely rule out XPLN being 
a target of mTORC2 because of the existence of other RhoGEFs, we decided to examine 
the alternative possibility of XPLN being upstream of mTORC2. We used Akt as a 
readout because it was the best characterized substrate of mTORC2.  
As shown in Fig. 2.2A, Akt phosphorylation on Ser473, the mTORC2 site, was 
markedly increased upon XPLN knockdown in both HEK293 and C2C12 cells, with two 
independent shRNAs for each cell line. On the other hand, XPLN knockdown did not 
affect the mTORC1 substrate S6K1, or the phosphorylation of NDRG1 (substrate of 
SGK1 – another target of mTORC2) (Fig. 2.2A). The effect of XPLN depletion was 
observed on both steady-state and serum-stimulated Akt phosphorylation (Fig. 2.2A&B). 
Phosphorylation of T308 on Akt was not markedly affected by XPLN knockdown (Fig. 
2.2B), further confirming that XPLN acted through mTORC2. Several substrates of Akt 
are known to be differentially dependent on the phosphorylation status of Akt – while 
FoxO3a phosphorylation requires pS473, phosphorylation of TSC2 and GSK3b can occur 
in the absence of pS473 (Guertin et al., 2006; Jacinto et al., 2006). Indeed, XPLN 
knockdown did not affect the levels of pT1462-TSC2 and pS9-GSK3b, both markedly 
stimulated by serum (Fig. 2.2B). The level of FoxO3a, on the other hand, was drastically 
reduced upon XPLN knockdown in serum-stimulated cells (Fig. 2.2B), most likely a 
consequence of enhanced phosphorylation by hyperactive Akt (Plas and Thompson, 
2003). Furthermore, overexpression of XPLN resulted in a modest, but nevertheless 
statistically significant, reduction of serum- and insulin-stimulated pSer473-Akt, with a 
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similar effect on pT32-FoxO3a but no effect on pT346-NDRG1 (Fig. 2.2C). Taken 
together, these observations strongly suggest that XPLN is an endogenous inhibitor of 
Akt phosphorylation by mTORC2.  
 Since one of the major functions of Akt is to support cell survival, at least partly 
through regulation of FoxO (Greer and Brunet, 2005; Lawlor and Alessi, 2001), we tested 
whether XPLN might impact apoptosis. To examine this possibility, HeLa cells were 
serum-starved to induce apoptosis. As shown in Fig. 2.2D, XPLN knockdown decreased 
the levels of PARP cleavage as well as cleaved Caspase-3, both markers of apoptosis. 
Importantly, an Akt1/Akt2 inhibitor (Akti) and the mTOR kinase inhibitor Torin1 
reversed the protective effect of XPLN depletion and enhanced apoptosis (Fig. 2.2D), 
suggesting that XPLN acts through Akt and mTOR. This is further confirmed by the 
reversal of XPLN knockdown phenotype by the co-knockdown of rictor (Fig. 2.2E). It is 
noted that XPLN knockdown modestly enhanced pAkt even in rictor knockdown cells 
(Fig. 2.2E), most likely due to residual rictor protein especially in cells infected by both 
XPLN and rictor shRNA viruses, which had reduced rictor knockdown efficiency. In 
conclusion, XPLN negatively regulates cell survival by suppressing mTORC2 and Akt. 
 
2.3.3. XPLN regulation of Akt phosphorylation is independent of its GEF activity 
and dependent on its N-terminus. Because the only reported function of XPLN thus far 
is to act as a RhoGEF, we set out to test whether the GEF activity of XPLN was 
necessary for its regulation of Akt.  It has been reported that two point mutations, L321E 
in the DH domain and W492L in the PH domain, are each sufficient to inactivate the 
GEF activity of NET1, the closest homologue of XPLN (Alberts and Treisman, 1998). 
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We constructed analogous mutants of XPLN – L269E and W440L, and found that indeed 
each mutation abolished the GEF activity of recombinant XPLN when overexpressed in 
cells (Fig. 2.3A). Strikingly, these XPLN mutants suppressed Akt phosphorylation in 
cells to the same degree as WT XPLN (Fig. 2.3B). Consistent with a GEF-independent, 
mTORC2 binding-dependent function of XPLN, both GEF-inactive XPLN mutants 
interacted with mTORC2 (Fig. 2.3C). These observations suggest that XPLN regulates 
phosphorylation of Akt in cells independently of its GEF activity. 
To further examine the mechanism of XPLN action, we set out to map the 
region(s) of XPLN interacting with mTORC2. XPLN contains DH and PH domains with 
N- and C-terminal regions having no known sequence motifs. The DH domain of most 
GEFs confers the catalytic activity, whereas the PH domain may regulate protein 
localization by mediating protein-lipid or protein-protein interactions at least in some 
GEFs (Rossman et al., 2005). As shown in Fig. 2.3D, the N-terminal region of XPLN 
(amino acids 1-125, designated N125) and the PH domain (amino acids 304-466) 
interacted with endogenous mTOR and rictor, suggesting that XPLN may have two 
independent binding sites for mTORC2. Importantly, overexpression of XPLN-N125 
suppressed Akt phosphorylation to the same extent as overexpression of full-length 
XPLN (Fig. 2.3E). On the other hand, overexpression of the PH domain did not affect 
Akt (Fig. 2.3E) even though it interacted with rictor. Hence, we surmise that XPLN 
inhibits mTORC2 function via its N-terminus interacting with rictor. A second 
interaction, between the PH domain and rictor, may serve to strengthen the interaction 
and enhance the inhibitory function of the N-terminus of the full-length protein.  
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2.3.4. XPLN inhibits mTORC2 kinase activity towards Akt in vitro. Given the 
physical interaction between XPLN and mTORC2, and the lack of detectable interaction 
between XPLN and Akt (Fig. 2.7), we reasoned that the simplest model explaining our 
observations thus far would be the inhibition of mTORC2 activity through XPLN 
binding. XPLN did not disrupt mTORC2 assembly, as overexpression of XPLN did not 
affect the amount of mTOR co-immunoprecipitated with rictor (Fig. 2.8). To examine if 
XPLN had a direct effect on mTORC2 kinase activity, we performed in vitro kinase 
assays with endogenous mTORC2 immunoprecipitated through rictor, using Akt as a 
substrate. Addition of bacterially purified GST-XPLN, but not GST-Cdc42, to the 
reaction markedly inhibited phosphorylation of Akt (Fig. 2.4A). At the same time, GST-
XPLN had no effect on in vitro mTORC1 kinase activity using 4E-BP1 as a substrate 
(Fig. 2.4B).  
Next, we examined XPLN mutants for their capacity to impact mTORC2 kinase 
activity. As shown in Fig. 2.4C, the GEF-inactive mutant, W440L, inhibited Akt 
phosphorylation in vitro as effectively as the wt XPLN. The N125 fragment was also 
inhibitory, whereas XPLN with the N-terminal 125 amino acids deleted (DN-XPLN) had 
no effect on the kinase activity (Fig. 2.4C), indicating that N125 is both necessary and 
sufficient for XPLN’s inhibition of mTORC2. Hence, in line with its regulation of Akt 
phosphorylation in cells, XPLN directly inhibits mTORC2 by a GEF-independent 
mechanism through its N-terminus, most likely via physical interaction with the 
mTORC2 complex.  
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2.3.5. XPLN negatively regulates myoblast differentiation through mTORC2 and 
Akt. To further probe the biological relevance of this novel role of XPLN in regulating 
mTORC2 and Akt, we set out to examine a potential function of XPLN in myoblast 
differentiation, because XPLN expression has been reported to be the highest in skeletal 
muscles among human tissues (Arthur et al., 2002) and, additionally, Akt is a well-
established regulator of skeletal myogenesis (Jiang et al., 1999; Peng et al., 2003). To that 
end, C2C12 myoblasts were induced to undergo myogenic differentiation by serum 
withdrawal. XPLN depletion led to a significant enhancement in myoblast differentiation 
compared to the control cells, as evidenced by elevated expression of the myogenic 
markers, myosin heavy chain (MHC) and myogenin (Fig. 2.5A), as well as increased 
fusion index (Fig. 2.5B). This XPLN knockdown phenotype was recapitulated in mouse 
primary myoblasts (Fig. 2.5A&B).  
To determine the function of XPLN in muscle regeneration, we injected 
lentiviruses expressing shRNA against XPLN together with BaCl2 into tibialis anterior 
muscles. Interestingly, XPLN depletion enhanced muscle regeneration (Fig. 2.11), as 
depicted by the increase in muscle cross-section area (CSA) compared to the control 
shRNA.  
 XPLN overexpression decreased the degree of C2C12 differentiation (Fig. 
2.5C&D), which corroborated the knockdown phenotype. Interestingly, overexpression 
of the GEF-inactive mutants, as well as the N-terminal fragment of XPLN, had the same 
inhibitory effect on differentiation as WT XPLN (Fig. 2.5C&D), indicating that the anti-
myogenic function of XPLN is independent of its GEF activity and is conferred by its N-
terminus. This function closely correlates with the mode of XPLN action on Akt activity.  
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Furthermore, knockdown of rictor suppressed the increase in differentiation 
induced by XPLN knockdown (Fig. 2.5E&F), confirming that XPLN acts through 
mTORC2. Similar to the observations in HeLa cells (Fig. 2.2E), co-knockdown led to 
less efficient depletion of rictor protein, which could explain the increased pAkt 
compared to rictor knockdown alone (Fig. 2.5E). The degree of differentiation correlated 
with the degree of pAkt (Fig. 2.5E&F). In addition, a constitutively active (c.a.) Akt 
overcame the inhibition by overexpressed XPLN and restored differentiation (Fig. 2.5G). 
Conversely, Akti severely impaired differentiation in cells with XPLN knockdown (Fig. 
2.5H). In aggregate, our observations strongly suggest that XPLN negatively regulates 
myoblast differentiation by inhibiting Akt activation, through suppression of mTORC2. 
 
2.4. Discussion 
 mTORC2 is critically involved in various cellular and developmental processes, 
but knowledge of its regulation has been scarce. Our studies have identified XPLN as a 
direct mTORC2 inhibitor in cells and in vitro. XPLN inhibits the kinase activity of 
mTORC2 towards Akt. This function of XPLN does not require its GEF activity and is 
most likely mediated by its direct interaction with mTORC2, revealing a non-canonical 
role of XPLN that is Rho-independent. Furthermore, we show that the endogenous XPLN 
negatively regulates cell survival and skeletal myoblast differentiation through inhibiting 
mTORC2 and Akt, validating the biological significance of this newly discovered 
regulatory mechanism. The only other mTORC2-specific inhibitor reported, GILZ, has 
been shown to inhibit mTORC2/Akt signaling when overexpressed in BCR-ABL-
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positive CML cells (Joha et al., 2012), but it is not known whether GILZ is an 
endogenous inhibitor of mTORC2 in normal physiological contexts. 
Several RhoGEF proteins have been reported to have GEF activity-independent 
functions. For example, the GEF activity of Vav1 is not necessary for its ability to 
potentiate NF-AT activation in response to T cell receptor signaling (Kuhne et al., 2000). 
Dbl binds and translocates Ezrin to the plasma membrane in a GEF-independent manner 
(Vanni et al., 2004). The exact mechanisms by which such non-canonical functions are 
exerted by these GEFs are not clear, although protein-protein interactions mediated by 
modular domains outside of the catalytic region appear to be important. Interestingly, 
XPLN binds and inhibits mTORC2 via an N-terminal region that lacks sequence 
homology to any known modular domain. A second binding site is found in the PH 
domain of XPLN, but this domain is not sufficient to elicit an effect on mTORC2. It is 
possible that this additional interaction serves to increase the overall affinity between 
XPLN and mTORC2, in which case overexpression of the N-terminus resulting in a high 
local concentration would be sufficient to exert an inhibitory effect without the need for 
the PH domain, as we have observed. 
Interestingly, the action of XPLN is not only specific for mTORC2 but may even 
be selective toward Akt. Another substrate of mTORC2, SGK1, is not regulated by 
XPLN in cells. This contrasts the observation with DEPTOR, which inhibits the 
phosphorylation of all mTORC1 and mTORC2 substrates tested (Peterson et al., 2009). 
Overexpression of GILZ also inhibits all mTORC2 substrates in CML cells (Joha et al., 
2012). It is possible that endogenous XPLN is localized in the cell where Akt, but not 
SGK1, is regulated. However, the lack of effect on SGK1 by XPLN overexpression  
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(Fig. 2.2C), which would presumably override any requirement for subcellular 
localization, seems to argue against that possibility. An alternative mechanism is that 
XPLN binding to mTORC2 specifically blocks Akt as a substrate without affecting the 
other mTORC2 substrates. Future biochemical and structural studies should prove 
informative for the dissection of the exact mechanism by which XPLN inhibits mTORC2 
phosphorylation of Akt. 
 Removal of XPLN inhibition alone is not sufficient to induce Akt 
phosphorylation in the absence of upstream stimuli when the basal activity of Akt is low. 
This is not surprising, as presumably activation of the kinase (mTORC2) requires 
positive inputs in addition to removal of XPLN suppression. Although very little is 
known about such inputs, PI3K activity and TSC1/2 have been reported to mediate 
mitogenic stimulation of mTORC2 kinase activity (Gan et al., 2011; Huang et al., 2008). 
It is presently not known how or whether XPLN itself is regulated. Growth factor 
stimulation activates Akt in cells, but it does not affect XPLN levels (Fig. 2.9A) or the 
interaction between XPLN and mTORC2 (Fig. 2.9B&C). DEPTOR is degraded by the 
proteasome in an mTOR-dependent fashion in response to serum stimulation, which 
forms a positive feedback loop to maximize mTOR activation (Duan et al., 2011; Gao et 
al., 2011; Zhao et al., 2011). However, the slow kinetics of DEPTOR degradation 
(Peterson et al., 2009) does not explain the well-known rapid activation of mTORC1 and 
mTORC2 substrates upon growth factor stimulation. It is possible that the inhibitors – 
DEPTOR and XPLN alike – may be overcome by a conformational change or 
modification of the kinase (mTORC2) without physical removal. In the case of XPLN in 
myoblast differentiation, there may be a simple mechanism of de-repression: the level of 
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XPLN does not change (Fig. 2.10), but mTOR levels increase drastically in the course of 
differentiation, which may allow mTORC2 to overcome XPLN stoichiometrically.  
Akt regulates many physiological processes in addition to cell survival and 
myogenic differentiation, including cell proliferation, glucose metabolism, and other 
types of cellular differentiation. Regulation of Akt by XPLN in those processes warrants 
future investigation. A proto-oncogene, Akt is involved in tumorigenesis by promoting 
proliferation, survival, and motility of cancer cells (Vivanco and Sawyers, 2002). 
Evidence supports a direct role of mTORC2, at least partly through Akt, in driving 
tumorigenesis (Zoncu et al., 2011). Future examination of a role of XPLN in tumor 
suppression, especially in the context of hyperactive Akt, may prove informative for the 
understanding of and therapeutic strategy against cancer. 
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2.5. Figures 
 
 
Fig. 2.1. XPLN interacts with mTORC2.  (A) HEK293 cells stably expressing Flag-
mTOR were transfected with Myc-XPLN. Anti-Myc or anti-Flag immunoprecipitation 
(IP) was followed by Western analysis. (B-C) GST pull-down assays were performed 
using purified GST-XPLN with GST as a negative control with HEK293 (B) or C2C12 
(C) cell lysates, and analyzed by Western blotting. Some degradation fragments were 
present in the GST-XPLN protein preparation. (D) Endogenous rictor and mSin1 were 
IPed from HEK293 cells stably expressing Myc-XPLN, followed by Western analysis. 
(E) C2C12 cells were infected with lentiviruses expressing shRNAs for mTOR, raptor, 
rictor, or a scrambled sequence as control, and then subjected to GST-XPLN pull-down 
assays.  
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Fig. 2.2. XPLN negatively regulates Akt phosphorylation and cell survival. (A) 
HEK293 or C2C12 cells were infected with lentiviruses expressing two independent 
XPLN shRNA (“X1”, “X2”), or a scrambled hairpin sequence as control (“C”), followed 
by Western analysis. Due to its lower abundance in HEK293 cells, XPLN was enriched 
by immunoprecipitation before Western blotting. (B) HEK293 cells were treated as in A 
and then serum starved overnight, followed by stimulation with 10% FBS for 30 min 
before Western analysis. (C) C2C12 cells were transfected with Myc-XPLN. After serum 
starvation overnight, the cells were stimulated with 10% FBS or 100 nM insulin for 30 
min followed by Western analysis. pS473-Akt and Akt bands were quantified by 
densitometry, and the relative ratios of pS473 versus total Akt were calculated with 
empty vector-transfected and stimulated samples designated as 1. One-sample t test was 
performed to compare each data point to its respective control. *P<0.05. (D) HeLa cells 
were infected with XPLN shRNA1 (“X”) or control, serum starved for 48 hrs, followed 
by Western analysis. Some cells were treated with 1 µM Akti or 250 nM Torin1 for 3 hrs 
prior to cell lysis. (E) HeLa cells were infected with XPLN or rictor (“R”) shRNA, or 
both, serum starved for 48 hrs, followed by Western analysis. 
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Fig. 2.3. XPLN regulation of Akt is independent of its GEF activity and dependent 
on its N-terminus. (A) HEK293 cells were transfected with wild type, L269E, or W440L 
Myc-XPLN, followed by GST-RBD pull-down assays. The active RhoA (RhoA pulled 
down with GST-RBD), and total RhoA (RhoA in cell lysates) were quantified by 
densitometry. The ratios of active RhoA versus total RhoA were calculated and 
normalized against the control (empty vector). Paired t tests were performed to compare 
each data point to vector control. **P<0.005.  (B) C2C12 cells were transfected with 
various Myc-XPLN as indicated, followed by Western analysis. (C) HEK293 cells were 
transfected with various Myc-XPLN, followed by anti-Myc IP and then Western analysis. 
(D) HEK293 cells were transfected with fragments of Myc-XPLN as indicated, followed 
by anti-Myc IP and then Western analysis. (E) C2C12 cells were transfected with various 
Myc-XPLN fragments, followed by Western analysis. 
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Fig. 2.4. XPLN inhibits mTORC2 phosphorylation of Akt in vitro. (A) Endogenous 
rictor was immunoprecipitated (IP) from HEK293 cells, and subjected to in vitro kinase 
assays using His-Akt as the substrate and anti-pSer473 as the readout. Bacterially 
purified GST-XPLN or GST-Cdc42 (1 μg each) was added prior to kinase assays in the 
indicated samples. (B) Endogenous raptor was immunoprecipitated, and subjected to in 
vitro kinase assays using GST-4EBP1 as the substrate and anti-pThr37/46 as the readout. 
GST-XPLN or GST (1 μg each) was added prior to kinase assays in the indicated 
samples. (C) Endogenous rictor immunoprecipitation and in vitro kinase assay were 
performed as described in A. Bacterially purified GST fusion protein of XPLN, W440L-
XPLN, N125-XPLN, or DN-XPLN (1 μg each) was added prior to kinase assays. 
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Fig. 2.5. XPLN negatively regulates myoblast differentiation through mTORC2 and 
Akt. (A) C2C12 myoblasts and mouse primary myoblasts (PM) were infected with 
lentiviruses expressing XPLN shRNA (“X1”, “X2”), or the control hairpin (“C”). After 
differentiation for 3 days (C2C12) or 2 days (PM), the cells were subjected to Western 
analysis. (B) Cells as described in A were fixed and stained for MHC and DAPI, and 
quantified for fusion index. (C) C2C12 cells were transfected with WT, mutants, or 
fragments of XPLN as indicated. After differentiation, the cells were subjected to 
Western analysis. (D) Cells as described in C were stained for MHC and DAPI, and 
quantified for fusion index. (E) C2C12 cells were infected with lentiviruses expressing 
shRNA for XPLN, rictor, or both. After differentiation, the cells were subjected to 
Western analysis. (F) Cells as described in E were stained for MHC and DAPI, and 
quantified for fusion index. (G) Cells were transfected with Myc-XPLN, c.a.-Akt, or 
both, followed by differentiation and then Western analysis. (H) Cells were infected with 
XPLN shRNA lentivirus, differentiated in 1 μM Akti or DMSO, followed by Western 
analysis. Paired t test was performed to compare each data point to control. *P<0.05. 
**P<0.01.  
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Fig. 2.6. Knockdown of mTORC2 does not affect RhoA-GTP loading. HEK293 cells 
were infected with lentiviruses expressing shRNAs for mTOR, rictor, or a scrambled 
sequence as control. Cell lysates were subjected to GST-RBD pull-down assays followed 
by Western analysis. Active RhoA (RhoA pulled down with GST-RBD), and total RhoA 
(RhoA in cell lysates) were quantified by densitometry. The ratios of active RhoA versus 
total RhoA were calculated and normalized against the control (scramble). Each data 
point is compared with the control by paired t test, and no significant difference was 
found. 
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Fig. 2.7. There is no detectable interaction between XPLN and Akt. HEK293 cell 
lysates were subjected to pulldown assay with GST-XPLN or GST, and endogenous Akt 
was detected by Western. 
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Fig. 2.8. Overexpression of XPLN does not affect mTOR-rictor interaction. HEK293 
cells were transfected with Myc-XPLN. Cell lysates were subjected to endogenous rictor 
IP followed by Western analysis. 
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Fig. 2.9. Serum stimulation does not affect XPLN protein level or its interaction with 
mTORC2. (A) HEK293 cells were serum-starved overnight and then stimulated with 
10% FBS for 30 min or 4 hrs, followed by Western analysis. (B) HEK293 cells were 
transfected with Myc-XPLN, serum-starved overnight followed by stimulation with 10% 
FBS for 30 min. IP was performed with anti-Myc antibody. (C) HEK293 cells were 
serum-starved and then stimulated with 10% FBS for 30 min, followed by GST pulldown 
assays.  
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Fig. 2.10. XPLN protein level does not change during myoblast differentiation. 
C2C12 cells were lysed before (myoblast – “MB”) or after (myotube – “MT”) 3-day 
differentiation, and subjected to Western analysis. 
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Fig. 2.11. XPLN depletion promotes muscle regeneration. Control or XPLN shRNA 
expressing lentiviruses were co-injected with BaCl2 into TA muscles. Regenerating 
muscles after 5 days of injection were cryosectioned and subjected to H&E staining. 
These sections were quantified for regenerating myofiber cross-section area (CSA). Data 
is plotted as mean ± S.D (n=5). A paired t-test was performed to compare each value with 
that of the control. **p<0.01 
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CHAPTER 3. CHARACTERIZATION OF XPLN LOCALIZATION 
AND FUNCTION 
 
3.1. Introduction 
 Once XPLN was established as an endogenous inhibitor of mTORC2 and Akt 
(Chapter 2), we wanted to probe into the mechanisms by which XPLN may be regulated 
in cells. Stimuli that are capable of activating mTORC2 activity towards Akt should 
somehow remove XPLN to allow Akt activation. Although, the exact stimuli that activate 
mTORC2 are ill defined, serum and growth factors are frequently used to stimulate 
mTORC2 activity.  
First possible mechanism examined was regulation of XPLN protein itself or 
regulation of the interaction between XPLN and mTORC2 by serum. Surprisingly, 
neither the XPLN protein levels changed nor did the interaction between XPLN and 
mTORC2 after serum stimulation (Fig. 2.9). Although, there wasn’t a dramatic change in 
the interaction between the two, one can never rule out a small but significant change in 
the interaction that can possibly be detected by more sensitive methods. Future 
biochemical and structural studies will further probe into this possibility.  
Here we investigate possible ways by which XPLN could be regulated in cells in 
order to allow Akt activation following growth factor stimulation. To probe potential 
regulation of XPLN function in the cell, I investigated the subcellular localization of 
XPLN, as well as the function and localization of alternative isoforms of XPLN. 
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3.2. Materials and Methods 
3.2.1. Antibodies and other reagents. Anti-GFP was from Roche, anti-tubulin antibody 
was from Abcam, and all other primary antibodies were from Cell Signaling Technology. 
All secondary antibodies were from Jackson ImmunoResearch Laboratories, Inc.  
3.2.2. Plasmids. For NLS, oligonucleotides: ATTGAAGAAGAAGCGGAAGGTGGA 
GG and AATTCCTCCACCTTCCGCTTCTTCTTC and for NES, oligonucleotides:  
AATTGCTGCAGCTGCCTCCTCTGGAGCGGCTGACCCTGG and  
AATTCCAGGGTCAGCCGCTCCAGAGGAGGCAGCTGCAGC were used. 
Oligonucleotides were annealed and ligated into the EcoR1 site of the original vector 
encoding XPLN-YFP in pEYFP-N1. Positive colonies containing directional inserts were 
screened by PCR using CMV+ primer and NLS- or NES- primer. To generate transcript 
#1 and transcript #2 encoding XPLN-YFP plasmids, gene block fragments consisting of 
the first 750 nucleotides were bought from IDT. They were then ligated into 
PshA1/EcoR1 digested parental XPLN-YFP-transcript #3 vector. GFP-Akt in the vector 
backbone pEGFP-C1 was bought from Addgene (plasmid # 39531). 
3.2.3. Cell culture. C2C12 myoblasts and HeLa cells were maintained in DME 
containing 10% fetal bovine serum (FBS) at 37 °C with 7% and 5% CO2 respectively. 
IGROV-1 cells were maintained in RPMI containing 10% fetal bovine serum (FBS) at 37 
°C with 5% CO2. Transfections were performed using Lipofectamine-2000 following the 
manufacturer’s recommendations.  
Following transfection, cells on coverslips were fixed, and stained for DAPI. The 
stained cells were examined with a Leica DMI 4000B fluorescence microscope, and the 
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fluorescent images were captured using a RETIGA EXi camera and analyzed with Q-
capture Pro51 software (Q-ImagingTM).  
3.2.4. Western blotting. Cells were lysed in ice-cold lysis buffer (40 mM HEPES, 
pH7.2, 120 mM NaCl, 10 mM pyrophosphate, 50 mM NaF, 10 mM b-glycerophosphate, 
2 mM EDTA, 1x Sigma protease inhibitor cocktail, and 0.3% CHAPS). The supernatant 
after microcentrifugation at 13,000 rpm for 10 min was collected and then boiled in SDS 
sample buffer. Proteins were resolved on SDS-PAGE and transferred onto PVDF 
membrane (Millipore), followed by incubation with various antibodies according to the 
manufacturers’ recommendations. Detection of horseradish peroxidase-conjugated 
secondary antibodies was performed with Western LightningTM Chemiluminescence 
Reagent Plus (Perkin Elmer, Inc.).  
 
3.3. Results 
3.3.1. Nuclear-cytoplasmic localization of XPLN. To examine the localization of 
XPLN, I transfected cells with a plasmid expressing XPLN-YFP followed by 
immunofluorescence studies. As shown in Fig. 3.1A, although the protein is diffused 
across the entire cell, the majority of the protein is concentrated in the nucleus. This 
pattern of localization is consistent among a variety of cell lines tested such as HeLa, 
IGROV-1, C2C12, HEK-293, MCF-7, MDA-MB-231, PC-3, HepG2, Hep-3b, TD-47, 
H661, H292, and U2OS (Fig. 3.1A).  
Next, I wanted to examine the localization of the endogenous protein. Since no 
XPLN antibody is available to specifically detect the endogenous protein by 
immunostaining, we performed subcellular fractionation experiments. HeLa cells were 
	   54	  
processed to generate two distinct fractions, nuclear and cytoplasmic, the latter consisting 
of everything except nucleus. To investigate a potential regulation of the localization, 
fractionation was performed under serum starvation and serum stimulation conditions. 
Comparing lanes 1,2 vs 3,4 in Fig. 3.1B, PARP is present exclusively in the nuclear 
fraction, as one would expect for a nuclear marker. On the other hand, MEK and tubulin 
are limited to the cytoplasmic fraction, as should be the case for cytoplasmic markers 
(Fig. 3.1B). Interestingly, XPLN is present predominantly in the nuclear fraction 
(comparing lane 1 vs 3 of Fig. 3.1B) in comparison to the cytoplasmic fraction under 
serum starvation conditions. Surprisingly, the majority of the XPLN protein disappears 
after serum stimulation from both cytoplasmic and nuclear fractions (lanes 2, 4 of Fig. 
3.1B). This disappearance of XPLN protein cannot be accounted for by the loss of total 
protein following serum stimulation since MEK, tubulin, and PARP showed no change in 
the levels before or after serum starvation. This is especially interesting considering the 
fact that total amount of XPLN protein did not change following serum starvation and 
stimulation (Fig. 2.9A). Although, I do not have explanation for this observation, it is 
possible that when stimulated with serum, the XPLN protein might have undergone some 
conformational change and become more susceptible to the proteases in the lysates.  
 
3.3.2. Manipulation of XPLN localization and the effect on Akt phosphorylation. 
Once the XPLN localization was confirmed to be mostly nuclear by both fractionation 
and immunofluorescence studies, I wanted to perturb this localization and analyze its 
effect on Akt phosphorylation. To this end, I tagged XPLN-YFP construct separately 
with a nuclear localization signal (NLS) and a nuclear export signal (NES). As shown in 
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Fig. 3.2A, NLS-XPLN-YFP was almost exclusively nuclear, whereas NES tagged 
XPLN-YFP was less concentrated in the nucleus than the wildtype XPLN-YFP, and 
rather diffusely present throughout the cell.  
 Next, I co-expressed GFP-Akt along with various XPLN-YFP proteins in cells 
and analyzed the effect of NLS-, NES- tagged XPLN-YFP on Akt phosphorylation. GFP 
tag allowed easy separation of GFP-Akt from endogenous Akt during western blotting 
making distinct analysis of exogenous Akt phosphorylation plausible. Surprisingly, when 
over-expressed both exclusively nuclear and more cytoplasmic versions of XPLN were 
capable of inhibiting the Akt phosphorylation to a similar extent as wild-type XPLN-YFP 
(Fig. 3.2B).  
 
3.3.3. Localization of alternative transcripts of XPLN. In mammals, XPLN coding 
sequence is alternatively spliced to generate different transcript isoforms that differ in the 
N terminal exons (Fig. 3.3A). These splice isoforms differ in the first ~ 60 amino acid 
residues at the N terminus of the protein (Fig. 3.3B). This is extremely interesting 
considering the fact that the N terminal fragment of XPLN consisting of 125 amino acids 
is necessary and sufficient to inhibit Akt phosphorylation by mTORC2 (Fig. 2.4C).  
 I first examined the localization of the protein products of these alternate 
transcripts by immunofluorescence experiments. Construct encoding transcript #3 was 
used for all the experiments in Chapter 2. As shown in Fig. 3.4A, transcript #1 is almost 
exclusively nuclear, in contrast to the transcript #3 and transcript #2. This is consistent 
with the fact that transcript#1 contains a predicted 6-amino acid nuclear localization 
signal (Fig. 3.3B).  
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3.3.4. Effect of over-expression of alternative transcripts of XPLN on Akt 
phosphorylation. Next, I examined how each of these XPLN transcripts individually 
affects Akt phosphorylation. YFP-fusion of the 3 transcripts were co-expressed with 
GFP-Akt in IGROV-1 cells. As shown in Fig. 3.4B, over-expression of transcript 
isoforms #1 and #2 was capable of reducing GFP-Akt phosphorylation to a similar extent 
as the transcript #3. Similar effect of XPLN transcripts on Akt phosphorylation was also 
seen in C2C12 cells (data not shown).  
 
3.4. Discussion  
In this chapter, I examined various possible ways by which XPLN could be 
regulated. XPLN protein was predominantly present in the nucleus. Serum starvation and 
stimulation did not change the localization of XPLN (data not shown). Furthermore, 
constitutively nuclear and cytoplasmic XPLN inhibited Akt phosphorylation to the same 
extent as the WT-XPLN (Fig. 3.2B) raising doubts over any role-played by XPLN 
localization towards regulating its inhibitory activity towards Akt. Although, the results 
may be complicated by the fact that the NLS and NES tagged XPLN proteins were over-
expressed on top of the endogenous XPLN protein. Same is true for the effect of over-
expression of various XPLN proteins differing in the first 60 amino acids on Akt 
phosphorylation. Only conclusion that can be obtained from the experiment is that each 
protein is equally capable of inhibiting Akt phosphorylation when over-expressed. A 
cleaner system would be to knock out XPLN gene altogether to eliminate all endogenous 
protein isoforms and then introducing one transcript at a time in a physiological amount 
to examine its effect on Akt phosphorylation. I am currently in the process of knocking 
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out XPLN gene in mouse (Appendix B). Mouse embryonic fibroblasts derived from the 
knockout mouse will then be utilized as an excellent system to address these questions.   
Presence of XPLN in the nucleus was a surprising finding for an mTORC2 
regulator since there is little mTORC2 activity in the nucleus (Rosner and 
Hengstschlager, 2008; Staus et al., 2014). Future experiments will examine the possibility 
of nuclear sequestration of XPLN. In fact, it was earlier believed that Net1 is sequestered 
in the nucleus (Schmidt and Hall, 2002) and Rac1 activation allows translocation of Net1 
to plasma membrane (Carr et al., 2013). Additionally, Rac1 has been proposed to localize 
mTORC2 and regulate its activation (Saci et al., 2011). To examine if XPLN could be 
regulated by Rac1, I coexpressed constitutively active Rac1 along with XPLN-YFP. 
Presence of c.a. Rac1 had no effect on the localization of XPLN (data not shown). In 
contrast, some recent evidence points to the existence of RhoA in nucleus (Dubash et al., 
2011; Rajakyla and Vartiainen, 2014). Future experiments will further probe into a 
potential role of nuclear XPLN as a GEF for RhoA in nucleus. 
XPLN adds to the growing list of RhoGEF proteins that are known to have GEF 
activity-independent functions (Rossman et al., 2005). The exact mechanism by which 
such non-canonical functions are exerted by these GEFs is not clear, although protein-
protein interactions mediated by modular domains outside of the catalytic region are 
proposed to play a role. DH-associated PH (pleckstrin homology) domains are the most 
well-characterized domains for this purpose. For many of the Dbl family members, PH 
domains allow membrane targeting by binding lipids (Rossman et al., 2003). More 
recently, PH domains gained acceptance as protein docking sites besides acting as lipid 
binding modules (Bellanger et al., 2000; Bellanger et al., 2003). An interesting example 
	   58	  
is the binding of PH domain of Dbl with Ezrin, linking plasma membrane with actin 
cytoskeleton (Vanni et al., 2004). In fact, the PH domain of XPLN is capable of binding 
mTORC2 when expressed alone, though is not sufficient to elicit an effect on mTORC2 
kinase activity (Chapter 2). It is highly likely that the PH domain plays a role in 
conferring the localization to XPLN. Besides PH domains, PDZ domains are also 
proposed to play a crucial role in localization of GEFs (Garcia-Mata and Burridge, 2007; 
Garcia-Mata et al., 2007).  
Outside the DH-PH domains, Dbl family proteins show considerable sequence 
diversity and typically contain domains that underlie the unique functions of the protein 
(Rossman et al., 2005). In fact, XPLN binds and inhibits mTORC2 via an N-terminal 
region that lacks sequence homology to any known modular domain (Chapter 2). This is 
particularly interesting considering the fact that the XPLN gene is alternately spliced in 
mammals to generate transcript isoforms that differ in their N terminal sequences.  
An intriguing possibility is the regulation of XPLN through phosphorylation. In 
fact, XPLN is predicted to contain several phosphorylatable amino acid residues by the 
online softwares (such as netphos2.1) that search for consensus sequences of various 
kinases. Although, XPLN is not part of the published HeLa phosphoproteomic database, 
this data cannot completely exclude a phosphorylation event, specifically if the 
phosphorylation takes place under specific cell conditions or is rapidly turned over. 
Hence, it is worth taking a candidate approach with a list of potential kinases in future. 
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3.5. Figures 
 
Fig. 3.1. XPLN is predominantly localized in the nucleus. (A) C2C12, HeLa and 
IGROV-1 cells were transfected with XPLN-YFP. After 24 hours, cells were fixed and 
stained with DAPI. (B) HeLa cells were starved of serum overnight followed by 
stimulation with 10% FBS for 30’. Cells were then fractionated to generate nuclear and 
cytoplasmic fractions (Performed by Dr. MeeSup Yoon). Images and blots are 
representatives of at least 3 independent experiments.  
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Fig. 3.2. Manipulation of XPLN localization and the effect on Akt phosphorylation. 
(A) IGROV-1 cells were transfected with WT- or NLS- or NES-XPLN-YFP. After 24 
hours, cells were fixed and stained with DAPI. (B) IGROV-1 cells were transfected with 
Myc-XPLN or WT- or NLS- or NES-XPLN-YFP along with GFP-Akt. After 24 hours of 
transfection, cells were lysed for western blotting. Images and blots are representatives of 
at least 3 independent experiments.  
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Fig. 3.3. Alternative splice isoforms of XPLN. (A) Image from ENSEMBL showing the 
exons in various isoforms. (B) Unique amino acids present at the N terminus of these 
transcripts.  
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Fig. 3.4. Localization and function of various XPLN transcripts. (A) IGROV-1 cells 
were transfected with various XPLN transcripts tagged with YFP. After 24 hours, cells 
were fixed and stained with DAPI. (B) IGROV-1 cells were transfected with various 
XPLN transcripts-YFP along with GFP-Akt. After 24 hours of transfection, cells were 
lysed for western blotting. Images and blots are representatives of at least 3 independent 
experiments.  
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CHAPTER 4. miRNA-146b PROMOTES MYOGENIC DIFFERENTIATION AND 
MODULATES MULTIPLE GENE TARGETS IN MUSCLE CELLS 2 
 
4.1. Introduction 
 
Skeletal myogenesis is a highly coordinated process involving myogenic lineage 
commitment, myoblast proliferation, differentiation and fusion. Myoblasts must undergo 
a complex series of molecular and morphological changes during this process, the exact 
mechanism of which is not completely understood. The life-long action of skeletal 
muscle relies on maintenance and regeneration of myofibers. Muscle repair is carried out 
by adult stem cells such as satellite cells present between plasma membrane and 
surrounding basal lamina of mature muscle fibers (Wagers and Conboy, 2005). 
Following injury, mitotically quiescent satellite cells re-enter cell cycle, divide and 
ultimately fuse with existing myofibers or with each other to promote repair and 
regeneration (Sabourin and Rudnicki, 2000). 
MicroRNAs (MiRNAs) are a class of small non-coding RNAs that have emerged 
as important modulators of gene expression (Bartel, 2009). There are more than 2500 
miRNAs in humans (miRBase.org) and they are predicted to target ~30-40% genes of the 
human genome. MiRNAs are involved in the regulation of many cellular and 
developmental processes as diverse as cell proliferation, cell survival, embryonic 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2 This chapter appeared in its entirety as: 
Khanna N., et al, 2014. MicroRNA-146b promotes myogenic differentiation and 
modulates multiple gene targets in muscle cells. PLoS One. 2014 Jun 23;9(6):e100657. It 
is available from 
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0100657 and 
using doi: 10.1371/journal.pone.0100657. 	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development and tissue differentiation (Felekkis et al., 2010; Stefani and Slack, 2008). 
Every aspect of skeletal myogenesis has been shown to be regulated by miRNAs (Ge and 
Chen, 2011). The activity of the miRNA processing enzyme, Dicer, is essential for 
normal muscle development during embryogenesis. Muscle-specific Dicer knockout mice 
have severely reduced muscle mass along with abnormal myofiber morphology leading 
to death within minutes of birth (O'Rourke et al., 2007). Various miRNAs have been 
shown to regulate key steps of skeletal myogenesis, of which the best-characterized 
myogenic miRNAs are miR-1, 206 and 133 (Chen et al., 2006; Chen et al., 2010; Kim et 
al., 2006). To date, 20 or so miRNAs have been reported to regulate myogenesis (Novak 
et al., 2013). Considering the prevalence of miRNA regulation in all aspects of biology, it 
is likely that additional myogenic miRNAs are to be identified. Indeed, expression 
profiling has revealed many miRNAs with differential expression patterns during 
myogenic differentiation (Sun et al., 2010), and they are likely candidates for novel 
myogenic regulators. 
MiR-146b is conserved among most vertebrates, and its expression increases 
during mouse prenatal development from E9.5 to E11.5 (Mineno et al., 2006). The 
function of miR-146b has been implicated in breast cancer metastasis (Hurst et al., 2009), 
innate immunity (Perry et al., 2009; Taganov et al., 2006), inflammation (Nakasa et al., 
2008), senescence (Bhaumik et al., 2009), and glioma cell migration and invasion (Xia et 
al., 2009). MiR-146b is also among the miRNAs identified in microarray studies to be 
up-regulated during satellite cell activation (Cheung et al., 2012) and myoblast 
differentiation (Sun et al., 2010), but a role of miR-146b in skeletal myogenesis has never 
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been reported. In the current study, we examined the potential function of miR-146b in 
myoblast differentiation.  
4.2. Materials and Methods  
4.2.1. Ethics statement. All animal experiments in this study were performed following 
protocols approved by the Animal Care and Use Committee at the University of Illinois 
at Urbana-Champaign, and conforming to the National Institutes of Health standards. 
4.2.2. Antibodies and other reagents. Anti-MHC (MF20) and anti-myogenin (F5D) 
were obtained from the Developmental Studies Hybridoma Bank developed under the 
auspices of the NICHD, National Institutes of Health and maintained by The University 
of Iowa, Department of Biological Sciences. Anti-tubulin was from Abcam. Antibodies 
against Hmga2, Smad4 and Notch1 were from Cell Signaling Technology. All secondary 
antibodies were obtained from Jackson ImmunoResearch Laboratories, Inc. All reagents 
were from Sigma-Aldrich. 
4.2.3. Cell culture and transfection. C2C12 myoblasts were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 1 g/L glucose with 10% fetal bovine 
serum at 37°C with 7.5% CO2. Primary myoblasts were maintained in F-10 medium 
supplemented with 25 ng/ml bFGF and 20% fetal bovine serum at 37°C with 7.5% CO2. 
To induce differentiation, cells were plated on tissue culture plates coated with 0.2% 
gelatin and grown to 100% confluence for C2C12 and 60-70% confluence for primary 
myoblasts, changed into differentiation medium (DMEM containing 2% horse serum), 
and replenished with fresh medium daily for 3 days for C2C12 cells and 2 days for 
primary myoblasts. HEK293 cells were maintained in DMEM containing 4.5 g/L glucose 
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with 10% fetal bovine serum at 37°C with 5.5% CO2. Transfections were performed 
using Lipofectamine 2000 (Invitrogen). 
4.2.4. Mouse primary myoblast isolation. Primary myoblast isolation was performed as 
described previously (Ge et al., 2011). Briefly, hind limb muscles from 5 to 7-day-old 
FVB mice were isolated and minced in HBSS, digested in dispase II (2.4 U/mL, Roche) 
and collagenase D (1.5 U/mL, Roche) solution containing 2.5 mM CaCl2 at 37°C for 2hr. 
Upon sequential filtering through 70 µm and 40 µm cell strainers (BD biosciences), the 
cells were collected by centrifugation at 350 g, and resuspended in F-10 culture medium. 
Serial plating was performed to enrich for myoblasts and eliminate fibroblasts. 
4.2.5. Mouse muscle injury and regeneration. Eight to 10-week-old male FVB mice 
were used in all the regeneration experiments. Muscle injury was induced by injection of 
barium chloride (BaCl2, 50 µL of 1.2% w/v in saline) into TA muscles as previously 
described (Ge et al., 2009). On various days after injury, the mice were euthanized and 
the TA muscles were collected, followed by RNA isolation. 
4.2.6. Plasmids and oligonucleotides. All the reporters were generated by inserting 
synthetic oligonucleotide DNA linkers of MRE sequences or their mutants into the 
pMIR-REPORTER vector (Applied Biosystems) downstream of luciferase gene through 
Hind III and Spe I sites. Native RNA duplexes for miR-146b and siEGFP (siRNA against 
EGFP) were custom-synthesized by Integrated DNA Technology. miRIDIAN miR-146b 
mimic and a negative control (cel-miR-67, which has no sequence identity with miRNAs 
in human, mouse and rat) were purchased from Dharmacon. Locked nucleic acid (LNA) 
anti-sense oligonucleotides were purchased from Exiqon, Inc. 
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4.2.7. Western blotting. Cells were lysed in a buffer containing 50 mM Tris-HCl, pH 
7.2, 150 mM NaCl, 1% NP-40, and 1% protease inhibitor cocktail (Sigma). The lysates 
were cleared by micro-centrifugation at 13000 rpm, and then mixed with SDS sample 
buffer. Proteins were resolved on SDS-PAGE and transferred onto PVDF membrane 
(Millipore), and incubated with various antibodies following the manufacturer’s 
recommendations. Detection of horseradish peroxidase-conjugated secondary antibodies 
was performed with Western LightningTM Chemiluminescence Reagent Plus (Perkin 
Elmer Life Sciences, Inc.), and images were developed on x-ray films. 
4.2.8. Immunofluorescence microscopy and quantitative analysis of myocytes. 
C2C12 cells differentiated in 12-well plates were fixed and stained for MHC and DAPI 
as previously described (Ge et al., 2011). The stained cells were examined under a Leica 
DMI 4000B microscope with a 10x dry objective (Leica Fluotar, numerical aperture 0.4), 
and the fluorescent images were captured at 8-bit at room temperature using a RETIGA 
EXi camera equipped with Qcapture Pro51 software (QImagingTM). The images were 
then pseudo-colored in Adobe Photoshop CS5, where brightness and contrast were 
adjusted. Fusion index was calculated as the percentage of nuclei in MHC-positive 
myotubes with ≥2 nuclei. Each data point was generated from randomly chosen 
microscopic fields containing in total 200 or more nuclei. 
4.2.9. Quantitative reverse transcription PCR (qRT-PCR). Mouse TA muscles were 
isolated, ground into powder in liquid nitrogen, and lysed in Trizol (Invitrogen). C2C12 
cells or mouse primary myoblasts were lysed directly in Trizol. RNA was isolated 
following the manufacturer’s protocol. Real-time PCR reactions were performed for 
Smad4, Notch1 and Hmga2 using Syber mix on a StepOnePlus system (Applied 
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Biosystems). β-Actin was used as a reference to obtain the relative fold change for target 
samples using the comparative CT method. The sequences of PCR primers are as 
follows. Smad4 forward: AGCCATAGTGAAGGACTGTTGCAG, Smad4 reverse: 
TACTTCCAGTCCAGGTGGTAGTGC; Notch1 forward: CACCTGTGACCTGCTCA 
CTC, Notch 1 reverse: ATTGGCACAGGGGTTGG A; Hmga2 forward: 
GTGCCACAGAAGC GAGGAC, Hmga2 reverse: GCTGCTTTAGAGGGGCTCTT. 
Mature miR-146b levels were quantified using a qPCR-based Taqman assay kit (Applied 
Biosystems). SnoRNA-202 was used as the internal control for normalization.  
4.2.10. Luciferase reporter assays. HEK293 or C2C12 cells transfected with the 
luciferase reporters were lysed in Passive Lysis Buffer (Promega), and luciferase assays 
were performed using the Luciferase Assay Systems kit (Promega) following the 
manufacturer’s protocol. 
4.2.11. Statistical analysis. All quantitative data are presented as mean ± standard 
deviation (SD). Whenever necessary, statistical significance of the data was analyzed by 
performing one-sample or paired t-tests. The specific types of tests and the P values, 
when applicable, are indicated in figure legends.  
 
4.3. Results 
4.3.1. MiR-146b expression is up-regulated during myogenesis. Our previous 
microarray profiling of miRNA expression revealed multiple miRNAs that were 
differentially expressed in differentiated versus undifferentiated mouse C2C12 
myoblasts, and miR-146b-5p was among those up-regulated upon differentiation (Sun et 
al., 2010). Dicing of pre-miR-146b stem loop gives rise to two distinct mature miRNA 
	   70	  
species, with miR-146-5p being the major and miR-146b-3p being the minor one 
(miRBase.org). For simplicity, we refer to miR-146b-5p as miR-146b from here on. Of 
note, all reagents used in this study were specific for miR-146b-5p. To validate the 
microarray data and further examine miR-146b expression, we performed qRT-PCR 
experiments with RNAs isolated from C2C12 cells over the course of differentiation 
induced by serum withdrawal. As shown in Fig. 4.1A, miR-146b levels increased steadily 
during differentiation and reached ~3.5-fold by day 3. This expression pattern was also 
observed during primary myoblast differentiation, albeit to a more modest degree (Fig. 
4.1B). 
We also examined miR-146b expression in vivo during muscle regeneration in a 
mouse model. BaCl2 was injected into tibialis anterior (TA) muscle to induce 
degeneration, followed by myofiber regeneration (Ge et al., 2009). As shown in Fig. 
4.1C, expression of miR-146b increased during day 3-5 after injury, a period of satellite 
cell activation and new myofiber formation, and returned to basal level after that. Taken 
together, these observations imply that miR-146b may have a positive role in 
myogenesis. 
 
4.3.2. MiR-146b positively regulates myoblast differentiation. To examine a possible 
role of miR-146b in myoblast differentiation, we inhibited miR-146b function in cells by 
delivering an anti-sense LNA-oligo by transfection, at an efficiency of ~75% as 
previously described (Ge et al., 2011). A scrambled LNA oligo with no sequence 
homology to any known miRNA was used as a control. As shown in Fig. 4.2A, 
transfection of LNA-anti-miR-146b into C2C12 cells led to inhibition of myotube 
	   71	  
formation. Quantification of myotubes revealed significant reduction in fusion index (Fig. 
4.2B). Anti-miR-146b also inhibited the expression of myosin heavy chain (MHC), a late 
marker of differentiation, with no significant effect on the early differentiation marker 
myogenin (Fig. 4.2C). We also examined the effect of miR-146b inhibition on primary 
myoblast differentiation, and found that anti-miR-146b suppressed differentiation as 
indicated by impaired myotube formation (Fig. 4.2D) and reduced fusion index (Fig. 
4.2E). Thus, miR-146b appears to be necessary for optimal myoblast differentiation. 
To further validate this positive function of miR-146b in myoblast differentiation, 
we introduced a chemically stabilized RNA duplex (miRIDIAN) of miR-146b into 
C2C12 myoblasts by transfection at ~90% efficiency as previously reported (Ge et al., 
2011). The C elegans miR-67 (cel-67), with no homology to any known mouse miRNA, 
was used as a control. Delivery of the stabilized miR-146b into myoblasts (equivalent of 
overexpressing miR-146b) led to enhanced myotube formation (Fig. 4.3A), elevated 
fusion index (Fig. 4.3B) as well as an increase in MHC expression, but no effect on 
myogenin expression (Fig. 4.3C). A native (unmodified) miR-146b duplex also increased 
fusion index (Fig. 4.3B), albeit to a lesser degree compared to the stabilized mimic. It is 
important to note that the passenger strand in the miR-146b miRIDIAN mimic, which 
was similar (but not identical) to miR-146b*, was chemically modified to prevent its 
incorporation into the RNA-induced silencing complex (RISC). The fact that the native 
duplex was less effective than the mimic further confirmed that the passenger strand 
(miR-146b*-like) was not responsible for the observed phenotype. Taken together, these 
data strongly suggest that miR-146b is a positive regulator of myoblast differentiation. 
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4.3.3. Smad4, Hmga2 and Notch1 are targets of miR-146b during myoblast 
differentiation. MiRNAs modulate gene expression by targeting mRNAs for 
translational repression and mRNA degradation. In most cases, miRNAs bind to their 
target mRNAs in the 3’UTR by imperfect base pairing. Perfect and contiguous base 
pairing of mature miRNA nucleotides 2 to 8 (seed region) to its target mRNA has been 
found to be critical for the majority of mRNA targeting (Bartel, 2009), although seedless 
targeting is also reported (Juan et al., 2009; Lal et al., 2009; Shin et al., 2010). 
Computational target prediction by miRanda, TargetScan and Pictar altogether yielded 
hundreds of putative targets for miR-146b. Because miRNAs almost always trigger the 
decay of their mRNA targets (Baek et al., 2008; Guo et al., 2010), within the predicted 
miR-146b target list we looked for genes that were reported to be down-regulated at the 
mRNA levels during differentiation of C2C12 cells as well as implied in myogenesis. We 
then examined the effect of miR-146b overexpression on the expression of each of those 
genes in C2C12 cells. Smad4, Hmga2 (high-mobility-group proteins containing AT-hook 
DNA binding domains), and Notch1 emerged as strong candidates for miR-146b targets 
because the expression of each was dampened by miR-146b overexpression (Fig. 4.4A). 
The modest degree of reduction (20-30%) in the mRNA levels is commonly observed for 
target genes in response to the overexpression of a single miRNA. Examples of genes not 
suppressed by miR-146b overexpression are also shown in Fig. 4.4A, including Ccna2, 
Suv39h1, Id1, and Hells. The increase of Ccna2 levels is likely an indirect effect of miR-
146b overexpression. Importantly, the protein levels of Smad4, Hmga2, and Notch1 were 
also reduced by the overexpression of miR-146b in myoblasts (Fig. 4.4B).  
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Protein levels for each of the putative targets of miR-146b have been reported to 
be down-regulated during myoblast differentiation (Conboy and Rando, 2002; Dey et al., 
2012; Li et al., 2012) (also see Fig. 4.5D), inversely correlating with the increased 
expression of endogenous miR-146b during myoblast differentiation (Fig. 4.1A&B). Of 
the three genes, Smad4 had previously been reported to be a miR-146b target in immune 
cells (Geraldo et al., 2012; Taganov et al., 2006), but its regulation in myoblasts by miR-
146b has never been examined. To gain further insight into the regulation of Smad4, 
Hmga2, and Notch1 during myoblast differentiation, we measured mRNA levels for each 
of these genes throughout the course of differentiation. As shown in Fig. 4.5A, a 
significant reduction in mRNA expression levels was observed for all three genes upon 
differentiation. Next, we examined the expression of these genes during muscle 
regeneration. We reasoned that the targets of miR-146b in regenerating muscles would be 
down-regulated upon miR-146b up-regulation. Indeed, we found that the mRNA levels of 
Smad4, Notch1 and Hmga2 were all reduced by 30-60% on day 3 and day 5 after injury 
(Fig. 4.5B). These expression patterns are perfectly in line with the possibility that miR-
146b targets these genes both in vitro and in vivo to impact skeletal myogenesis. 
Importantly, inhibition of endogenous miR-146b by the antisense LNA oligo almost 
completely prevented the decline in both mRNA and protein expression of Smad4, 
Hmga2, and Notch1 during myoblast differentiation (Fig. 4.5C&D), further supporting a 
critical role of miR-146b in suppressing those genes. 
 
4.3.4. MiR-146b directly targets the MREs in 3’UTRs of Smad4, Notch1, and 
Hmga2. 3’UTRs of Smad4 and Notch1 are each predicted to have a single miRNA 
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recognition element (MRE) for miR-146b, which is broadly conserved in vertebrates. 
Hmga2, on the other hand, contains 3 predicted MREs for miR-146b in its 3’UTR (Fig. 
4.6A). To assess whether miR-146b directly regulates one or more of these 3’UTRs, we 
constructed reporters containing one copy of each putative MRE downstream of the 
luciferase gene. These reporters were then transfected in HEK293 cells, a non-myogenic 
cell line with little endogenous miR-146b (data not shown), along with the miR-146b 
duplex. As shown in Fig. 4.6B, miR-146b targeted the Smad4 and Notch1 MREs, as 
indicated by the repression of reporter activities to a similar degree as its suppression of a 
positive control reporter containing sequences perfectly complementary to miR-146b. For 
Hmga2, miR-146b targeting was limited to only one of the three predicted MREs (Fig. 
4.6B). To further validate the specificity of the targeting, we constructed reporters with 
the seed regions mutated in the MREs (Fig. 4.6A). These mutant reporters were 
completely resistant to the presence of miR-146b duplex (Fig. 4.6B), confirming the 
specificity of the miR-146b action. To examine this targeting in a more physiologically 
relevant context, we expressed the MRE reporters in C2C12 cells, and introduced LNA-
anti-miR-146b. As shown in Fig. 6C, inhibition of endogenous miR-146b was sufficient 
to activate the reporters, suggesting that miR-146b normally suppresses those MREs in 
myocytes.  
 
4.4. Discussion 
Our results have identified miR-146b as a novel regulator of myoblast 
differentiation. In addition, we provide evidence to establish Smad4, Notch1 and Hmga2 
as direct targets of miR-146b during myoblast differentiation. Expression of miR-146b is 
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up-regulated during myoblast differentiation and muscle regeneration, accompanied by 
down-regulation of the target genes. Our previous miRNA profiling results indicated that 
miR-146b was the fourth most up-regulated miRNA after miR-1, miR-206, and miR-133 
upon differentiation of C2C12 cells (Sun et al., 2010). While the myogenic roles of the 
other three miRNAs have been well documented (Chen et al., 2006; Chen et al., 2010; 
Kim et al., 2006), this is the first report of miR-146b as a myogenic regulator, which also 
attests to the power of expression profiling in predicting function. New myogenic 
miRNAs may continue to be discovered by this approach. 
Major myogenic miRNAs, miR-1, miR-133, and miR-206, are expressed in 
muscles under the control of the myogenic transcription factors SRF, MyoD, and MEF2 
(Liu et al., 2007; Rao et al., 2006; Rosenberg et al., 2006; Zhao et al., 2005). One or more 
of those transcription factors may also regulate the expression of miR-146b. Another 
potential regulator is NF-κB, which has been reported to regulate miR-146b biogenesis in 
immune cells (Taganov et al., 2006). Future investigations will probe the mechanisms of 
miR-146b biogenesis in myogenesis. 
Transforming growth factor β (TGFβ)/bone morphogenetic protein (BMP) 
signaling pathways regulate satellite cell activation and proliferation during muscle 
development (Wang et al., 2010). TGFβ and BMP signal through specific Smad proteins, 
which on activation form a complex with the common regulator Smad4 to regulate gene 
expression. Similarly, Notch signaling is known to control satellite cell quiescence and 
activation (Bjornson et al., 2012; Conboy and Rando, 2002; Mourikis et al., 2012; 
Wilson-Rawls et al., 1999). In addition to regulating myoblast proliferation, these 
signaling pathways inhibit the transcriptional activity of myogenic regulatory factors 
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(MRFs) and prevent myoblast differentiation, maintaining muscle stem cell self-renewal 
(Kopan et al., 1994; Martin et al., 1992; Wilson-Rawls et al., 1999). Hmga2 is also a key 
regulator of satellite cell activation and proliferation both in vivo and in vitro (Li et al., 
2012). As cell cycle withdrawal is a prerequisite for myogenic differentiation, these 
regulators of myoblast proliferation need to be down regulated upon entering myogenic 
differentiation. In fact, forced expression of either Hmga2 or Smad4, or constitutive 
activation of Notch, is sufficient to prevent myoblast differentiation (Dey et al., 2012; Li 
et al., 2012; Wen et al., 2012). Here we provide compelling evidence for miR-146b 
regulation of these inhibitors of myogenesis. We propose that the increased level of miR-
146b during myogenesis serves to posttranscriptionally suppress Smad4, Notch1, and 
Hmga2 (and potentially other genes) in order to allow the activation of myogenic 
differentiation program. 
Smad4 has been shown to be targeted by miR-146b in human papillary thyroid 
cells on the same MRE as that on the mouse gene discovered in our study (Geraldo et al., 
2012), suggesting that this regulation may exist in multiple cell/tissue types. There are 
four mammalian Notch receptors, Notch1-4, of which Notch1 and 3 are known to be anti-
myogenic (Gagan et al., 2012; Shawber et al., 1996). Regulation of Notch3 by myogenic 
miRNAs, miR-1 and 206, has been reported (Gagan et al., 2012), and now our findings 
reveal targeting of Notch1 by miR-146b. Hence, a concerted suppression of Notch 1 and 
Notch 3 can be achieved, as miR-1, miR-206, and miR-146b are all up-regulated upon 
differentiation (Sun et al., 2010). 
It is now commonly accepted that the regulation of any gene is rarely controlled 
by a single miRNA. Rather, multiple miRNAs often coordinate to modulate the 
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expression of a gene (Tsang et al., 2010). It is unlikely that miR-146b is solely 
responsible for suppressing the target genes we have identified during myogenic 
differentiation. In fact, miR-26a has been reported to target Smad4 during myogenesis 
(Dey et al., 2012) and it is conceivable that miR-26a and miR-146b act together to 
regulate Smad4. Similarly, Hmga2 has been reported to be targeted by let-7 (Lee and 
Dutta, 2007) and miR-98 (Hebert et al., 2007) in cancer cells, both of which are up-
regulated during myoblast differentiation (Dmitriev et al., 2013; Kallen et al., 2013). 
Hence, a concerted targeting of Hmga2 by let-7, miR-98 and miR-146b during myoblast 
differentiation is possible. Regardless of the potential coordination, however, the 
contribution of miR-146b may be indispensible in bringing the levels of those genes 
below a threshold for the activation of the myogenic program to occur. This notion is 
supported by our observation that inhibition of miR-146b almost completely prevents 
down-regulation of Smad4, Notch1, and Hmga2 (Fig. 4.5C&D). 
MicroRNAs hold the potential as therapeutic targets or tools in aging and 
dystrophic muscles. For instance, over-expression of miR-1/206 suppresses rhabdomyo-
sarcoma development through c-met expression (Yan et al., 2009). Additionally, 
intramuscular injections of miR-1, miR-206, and miR-133 in rat skeletal muscle promote 
muscle regeneration (Nakasa et al., 2010), and so does intramuscular injection of anti-
miR-125b, a negative regulator of myogenesis (Ge et al., 2011) The physiological 
significance and therapeutic potential of miR-146b as a myogenic regulator warrants 
future investigations.   
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4.5. Figures 
 
 
Fig. 4.1. miR-146b expression is up-regulated during myogenesis. (A, B) C2C12 
myoblasts (A) and mouse primary myoblasts (B) were induced to differentiate. Total 
RNA was isolated from the differentiating cells on various days as indicated (diff. day) 
and subjected to analysis by qRT-PCR to determine the relative levels of mature miR-
146b with that on day 0 as 1. Data shown are mean ± SD from three to four independent 
experiments. (C) Regeneration of mouse TA muscles was induced by BaCl2 injury. On 
various days after injury (AI), total RNA was isolated from the TA muscles and subjected 
to analysis by qRT-PCR to determine the relative levels of mature miR-146b. Saline 
injection into contralateral TA muscles served as “no injury” control and was designated 
as 1. Data shown are mean ± SD with at least three mice per time point. One-sample t test 
was performed to analyze each data point. *P < 0.05; **P < 0.01. 
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Fig. 4.2. Inhibition of miR-146b suppresses myoblast differentiation. C2C12 
myoblasts (A-C) or primary myoblasts (D-E) were transfected with 50 nM LNA-anti-
miR-146b for 1 day and then induced to differentiate for 3 or 2 days, respectively. An 
LNA oligonucleotide with scrambled sequence served as a negative control. (A, D) The 
differentiated cells were fixed and immunostained for MHC (green) and DAPI (red).  
(B, E) Fusion indexes were quantified. (C) Cell lysates were subjected to Western blot 
analysis. In A, C, and D representative results of at least three independent experiments 
are shown. Data in B & E are shown as mean ± SD from three to four independent 
experiments. Paired t tests were performed to compare the data. *P < 0.05; **P < 0.01. 
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Fig. 4.3. Overexpression of miR-146b promotes myoblast differentiation. (A) C2C12 
myoblasts were transfected with 50 nM miRIDIAN miR-146b mimic for 1 day and then 
induced to differentiate for 3 days. A C elegans miRNA (cel-67) mimic was used as 
negative control. The differentiated cells were fixed and immunostained for MHC (green) 
and DAPI (red). (B) Fusion indexes for the cells described in A were quantified. In 
addition, cells transfected with 50 nM native miR-146b duplex, with an siRNA against 
EGFP (siEGFP) as control, were differentiated and quantified for fusion index. (C) Cells 
described in A were lysed and subjected to Western blot analysis. In A and C, 
representative results of at least three independent experiments are shown. Data in B is 
the mean ± SD from three independent experiments. Paired t test was performed to 
compare the data. *P < 0.05 
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Fig. 4.4. Overexpression of miR-146b suppresses expression of Smad4, Hmga2 and 
Notch1 in myoblasts. (A) C2C12 myoblasts were transfected with 50 nM miRIDIAN 
miR-146b mimic or cel-miR-67 mimic as control. After 24 hours, cells were lysed for 
RNA isolation, followed by qRT-PCR to measure mRNA levels for the genes shown. 
Relative mRNA levels are shown with that of cel-miR-67 as 1. Data shown are the mean 
± SD from three independent experiments. One-sample t test was performed. **P < 0.01. 
(B) Cells as described in A were lysed after 48 hours of transfection and subjected to 
Western blotting analysis. Representative results of three independent experiments are 
shown. 
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Fig. 4.5. Smad4, Hmga2 and Notch1 are targets of miR-146b during myoblast 
differentiation. (A) C2C12 cells were induced to differentiate, and total RNA was 
isolated from the differentiating cells on various days as indicated (Diff. day) and 
subjected to analysis by qRT-PCR to determine the relative levels of mRNA for each 
gene, with that at day 0 as 1. (B) Regeneration of mouse TA muscles was induced by 
BaCl2 injury. On day 3 and day 5 AI, the TA muscles were isolated for RNA extraction, 
followed by qRT-PCR assays to measure relative mRNA levels. Saline injection into 
contralateral TA muscles served as control (“-”) and was designated as 1. (C) C2C12 
cells were transfected with 50 nM LNA-anti-miR-146b or LNA control for 1 day and 
then induced to differentiate for 3 days. Total RNA was isolated on day 0 and day 3 of 
differentiation and analyzed by qRT-PCR. (D) Cells as described in C were lysed and 
subjected to Western blotting analysis. Data shown are mean ± SD from three to four 
independent experiments (A & C) or at least three mice per time point (B), or 
representative results of three independent experiments (D). One-sample t test was 
performed to analyze data in A & B, and paired t test was performed for data in C. *P < 
0.05; **P < 0.01. 
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Fig. 4.6. miR-146b directly targets the MREs in 3’UTRs of Smad4, Hmga2 and 
Notch1. (A) Predicted miR-146b target sites in the 3’UTRs of mouse Smad4, Notch1 and 
Hmga2 are shown. The nucleotides in the seed region that were changed to 
complementary sequence in the mutant 3’UTR reporters are indicated by lines above 
them. (B) The MRE reporters or their mutant counterparts were cotransfected with miR-
146b duplex into HEK293 cells, with siEGFP as a negative control. Twenty-four hours 
after transfection the cells were lysed and subjected to luciferase assays.  A sequence 
perfectly complementary to the active strand of miR-146b was cloned into the reporter 
and used as a positive control. (C) The MRE reporters were transfected into C2C12 cells 
together with 50 nM LNA-anti-miR-146b or LNA control for 1 day, followed by cell 
lysis and luciferase assays. All data shown are mean ± SD from three independent 
experiments. One-sample t test was performed to analyze each data in B&C. **P < 0.01.  
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CHAPTER 5. CONCLUSIONS AND PERSPECTIVES 
 
The protein kinase mammalian target of rapamycin (mTOR) is a master regulator 
of cell growth, survival, differentiation, and metabolism. Two biochemically unique 
protein complexes of mTOR – mTORC1 and mTORC2 – have distinct kinase activities 
and assemble signaling pathways that differentially regulate those cellular and 
developmental processes. As hyper-activation of mTOR signaling underlies many human 
diseases including diabetes and cancer, Nature has most likely designed intrinsic breaks 
for these pathways. Here, I identify one such control mechanism for mTORC2. The 
guanine nucleotide exchange factor (GEF) for Rho small GTPases, XPLN, was first 
found to interact with mTOR in a yeast two-hybrid screen. Experiments in mammalian 
cells subsequently revealed that XPLN specifically interacts with mTORC2, not 
mTORC1. XPLN inhibits mTORC2 kinase activity in vitro and signaling in cells. The 
inhibitory function of XPLN is specific for one of the targets of mTORC2 – the protein 
kinase Akt. In line with the well-established functions of Akt, XPLN negatively regulates 
cell survival and skeletal muscle differentiation through its inhibitory effect on mTORC2 
and Akt. Interestingly, this novel function of XPLN is independent of its GEF activity, 
but instead requires its N-terminal region, most likely via direct physical interaction with 
mTORC2.  
Akt regulates many physiological processes in addition to cell survival and 
myogenic differentiation, including cell proliferation, glucose metabolism, and other 
types of cellular differentiation. Regulation of Akt by XPLN in those processes warrants 
future investigation. A proto-oncogene, Akt is involved in tumorigenesis by promoting 
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proliferation, survival, and motility of cancer cells. Evidence supports a direct role of 
mTORC2, at least partly through Akt, in driving tumorigenesis. Future examination of a 
role of XPLN in tumor suppression, especially in the context of hyperactive Akt, may 
prove informative for the understanding of and therapeutic strategy against cancer. 
In search for novel miRNAs that regulate skeletal myogenesis, I identified miR-
146b as a regulator of myoblast differentiation and established Smad4, Notch1 and 
Hmga2 as direct targets of miR-146b. Expression of miR-146b is up-regulated during 
myoblast differentiation and muscle regeneration, accompanied by down-regulation of 
the target genes. MicroRNAs hold the potential as therapeutic targets or tools in aging 
and dystrophic muscles. For instance, over-expression of miR-1/206 suppresses 
rhabdomyo-sarcoma development through c-met expression (Yan et al., 2009). The 
physiological significance and therapeutic potential of miR-146b as a myogenic regulator 
warrants future investigations.   
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APPENDIX A.  EXPLORATION OF THE ROLE OF XPLN IN CANCER 
 
A.1. Materials and Methods 
A.1.1. Antibodies and other reagents. Anti-XPLN antibody was as described in Chapter 
II, anti-tubulin antibody from Abcam. All other primary antibodies were from Cell 
Signaling Technology. All secondary antibodies were from Jackson ImmunoResearch 
Laboratories, Inc.  
A.1.2. Cell culture. HeLa, U2OS, MCF-7, TD47, MDA-MB-231, H661, Calu-6, H292, 
and A549 cells were maintained in DME containing 10% fetal bovine serum (FBS) at 37 
°C with 5% CO2. IGROV-1 and PC-3 cells were maintained in RPMI containing 10% 
fetal bovine serum (FBS) at 37 °C with 5% CO2. Transfections were performed using 
Lipofectamine-2000 following the manufacturer’s recommendations. Viral transductions 
were performed as described earlier in Chapter II. 
A.1.3. Western blotting. Cells were lysed in ice-cold lysis buffer (40 mM HEPES, 
pH7.2, 120 mM NaCl, 10 mM pyrophosphate, 50 mM NaF, 10 mM b-glycerophosphate, 
2 mM EDTA, 1x Sigma protease inhibitor cocktail, and 0.3% CHAPS). The supernatant 
after microcentrifugation at 13,000 rpm for 10 min was collected and then boiled in SDS 
sample buffer. Proteins were resolved on SDS-PAGE and transferred onto PVDF 
membrane (Millipore), followed by incubation with various antibodies according to the 
manufacturers’ recommendations. Detection of horseradish peroxidase-conjugated 
secondary antibodies was performed with Western LightningTM Chemiluminescence 
Reagent Plus (Perkin Elmer, Inc.).  
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A.2. Results and Discussion 
A.2.1. Examination of XPLN copy number in various cancer databases. Hyperactive 
Akt signaling is frequently seen in cancer and we established XPLN to be an endogenous 
inhibitor of Akt activation. So, we next wanted to examine if XPLN gene was lost in 
tumor samples potentially contributing to Akt hyperactivation. To this end, I checked 
XPLN copy number in human tumor samples profiled by various databases. Interestingly, 
I found loss of XPLN DNA in a small number of tumor samples along with a small 
number of somatic mutations at a low frequency (Fig. A.1). Although, XPLN gene was 
amplified in some tumor samples, the amplification frequency was less than the deletion 
and mutation combined together. XPLN deletion can potentially nicely correlate with the 
Akt hyperactivation in these tumor samples.  
 
A.2.2. XPLN protein expression in different cancer cell lines. To directly examine 
XPLN level during different types of cancer, we decided to check the level of XPLN 
protein in various available cancer cell lines established from tumor tissues. Contrary to 
the expectations, XPLN protein level was comparable between cancer cell lines and 
corresponding epithelial normal cell lines (Fig. A.2A). Additionally, knockdown of 
XPLN in cancer cells had no effect on phospho Akt levels much in contrast to the 
enhanced pAkt seen after XPLN depletion in normal cells (Fig A.2B). So, we wondered 
if XPLN was somehow dysregulated in cancer cells allowing the cells to achieve 
hyperactivated Akt signaling without the need to physically remove XPLN.  
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A.2.3. Effect of XPLN over-expression on Akt phosphorylation in cancer cell lines. 
To examine this possible oncogenic mechanism of endogenous XPLN being 
dysregulated, I over-expressed recombinant XPLN in various cancer cell lines to check 
its effect on co-expressed GFP-Akt. We hypothesized that by over-expression of XPLN, 
we may overburden the machinery that normally regulates its function and hence allow 
over-expressed protein to elicit an effect on phospho Akt. In fact, this is exactly what we 
observed in IGROV-1 cells (first panel, Fig. A.3). I further extended this experiment to 
other cancer cell lines and noticed that there were two separate groups. First group, which 
showed inhibition of pAkt following XPLN over-expression, consisted of cell lines 
IGROV-1, PC-3, Calu-6, HeLa, U2OS, and Hep3B (Fig. A.3). In contrast, second group 
of cell lines were resistant to XPLN over-expression and showed no effect on pAkt levels 
following XPLN over-expression. This group of cell lines consisted of H-661, MDA-
MB-231, MCF-7, and A549 (Fig. A.3).  
  
A.2.4. Exploration of potential link between CDKN2A and XPLN. Next, I wanted to 
figure out why are some of the cancer cell lines resistant to XPLN overexpression. To 
probe this, I asked what is a common element for these resistant cell lines or how do they 
differ from the first set of cell lines that show sensitivity towards XPLN overexpression.  
 Since PTEN is an inhibitor of Akt signaling and a well-established tumor 
suppressor that is lost in a variety of tumor cell lines, we first looked at PTEN. IGROV-1 
and PC-3 are the only two PTEN null cell lines among all the cancer cell lines tested for 
the effect of XPLN overexpression on Akt phosphorylation. Since, both PTEN null and 
PTEN WT cell lines belong to the XPLN over-expression sensitive group cell lines, it 
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suggested that PTEN might not be the factor that regulates effect of XPLN over-
expression on Akt phosphorylation. 
 Next, I looked at other well-established tumor suppressors or oncogenes and 
found that all the cancer cell lines that were resistant to XPLN over-expression were 
CDKN2A null (Oncomine). The CDKN2A (INK4a, MTS1, CDKN2) gene locus is a 
unique gene locus in mammals that codes for 2 different proteins through splicing and 
alternate reading frames (Quelle, Zindy et al. 1995). It encodes p16INK4a, an inhibitor of 
the cyclin D-dependent kinases CDK4/CDK6 and hence inhibiting them from 
phosphorylating the retinoblastoma protein (pRB) and ultimately preventing exit from the 
G1 phase of the cell cycle (Quelle, Zindy et al. 1995). Second protein, p19ARF, arises 
from an alternative reading frame of the INK4a gene, and its ectopic expression induces 
both G1 and G2 phase arrest (Quelle, Zindy et al. 1995). ARF physically interacts with 
MDM2 to block MDM2 mediated degradation and transcriptional inactivation of p53 and 
hence activating p53 (Pomerantz, Schreiber-Agus et al. 1998).  
 To examine a potential role of p16INK4 in regulating Akt inhibition by XPLN, I 
knocked down INK4a in a CDKN2A WT cell line to check if it loses its sensitivity 
towards XPLN over-expression. As shown in Fig. A.4, knockdown of INK4a enhanced 
basal level of Akt phosphorylation, but XPLN over-expression was still capable of 
reducing pAkt levels even in INK4a depleted cells. This suggested that while INK4a 
itself may have a role in regulating Akt phosphorylation directly or indirectly through its 
effect on cell cycle (see below), it probably doesn’t regulate XPLN function towards Akt 
inhibition.  
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 Recently, a direct link between cell cycle and Akt phosphorylation was 
established (Liu, Begley et al. 2014). Specifically, it was shown that Akt activity 
mirrored cyclin A2 expression level during cell cycle and Cdk2/cyclin A2 was 
established as a physiological kinase to phosphorylate Akt1 at both S477 and T479 both 
in vivo and in vitro. Additionally, they showed that pS477/pT479 might prime Akt for 
mTORC2-mediated phosphorylation of S473. So, it is likely that INK4a depletion 
enhanced Akt phosphorylation through an indirect effect on cell cycle progression. 
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A.3. Figures 
 
Fig. A.1. Analysis of XPLN copy number in human tumor samples (Oncomine).  
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Fig. A.2. XPLN expression and effect of XPLN knockdown on phospho Akt levels in 
cancer cells. (A) Various cancer cells were transduced with XPLN virus followed by 
puromycin selection for 2-3 days. Cells were then lysed and lysates analyzed by western 
blotting. (B) Different cell lines were transduced with XPLN virus followed by 
puromycin selection for 2-3 days. Cells were then lysed and lysates analyzed by western 
blotting. Blots are representatives of at least 3 individual experiments.  
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Fig. A.3. Effect of XPLN over-expression on Akt phosphorylation in cancer cell 
lines. Various cancer cells were co-transfected with Myc-XPLN, GFP-Akt. Following 24 
hours of transfection, cells were lysed for western blotting. Images and blots are 
representatives of at least 3 individual experiments.  
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Fig. A.4. Effect of INK4a knockdown on XPLN mediated Akt inhibition. IGROV-1 
cells were transduced with lentiviruses followed by puromycin selection for 2 days. Cells 
were then transfected with Myc-XPLN and GFP-Akt. Following 24 hours of transfection, 
cells were lysed for western blotting. Images and blots are representatives of at least 3 
individual experiments.  
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APPENDIX B. CONSTRUCTION OF XPLN KO MOUSE USING TALEN 
TECHNOLOGY 
 
B.1. Materials and Methods 
B.1.1. C2C12 Transfection. pCS2+TALEN plasmids were constructed in collaboration 
with Zehua Bao in Huimin Zhao lab. C2C12 cells were transfected with 1.5 ug of each 
plasmid of the TALEN pair with Lipofectamine following manufacturer’s 
recommendations. Following 3 days of transfection, cells were lysed to isolate genomic 
DNA. 
B.1.2. TALEN mRNA production and embryo microinjection. 10 μg of pCS2+-
TALE plasmid was digested with 50 U of ApaI in a total reaction volume of 100 μl. 
Linearised plasmid was then gel purified and the DNA concentration was determined. 
For in vitro transcription, 20-μl transcription reaction was set up by using the reagents 
from the mMESSAGE mMACHINE SP6 Kit as follows: 10 μl of 2× NTP/CAP reagent, 
2 μl of 10× reaction buffer, 1 μg of template DNA, 2 μl Sp6 enzyme mix. Reaction was 
mixed by pipetting and incubated for 2 h at 37 °C. Following the incubation, 1ul Turbo 
DNase was added for 15’ at 37°C. RNA was purified by adding 350 μl of binding buffer 
from the MegaClear kit and 250 μl of ethanol. Sample was applied to a MegaClear spin 
column followed by performing RNA purification according to the manufacturer’s 
directions. To 100 μl of the eluted sample, 10 μl of 5 M ammonium acetate and 275 μl of 
ethanol were added for RNA precipitation and buffer exchange. Mixture was incubated 
overnight at −20 °C and centrifuged at 13krpm for 15 min at RT. Pellet was washed with 
500 μl of 70% ethanol (prepared with embryo-tested water) followed by air-drying the 
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pellet for 5 min. RNA pellet was then resuspended in 20 μl of T10E0.1 microinjection 
buffer (prepared with embryo tested water) followed by checking concentration using 
nanodrop and integrity of RNA by running on an agarose gel. Purified RNA from the 
TALEN pair plasmids was then microinjected by mouse facility in to one cell embryo. 
Animal housing and handling followed all relevant regulations and institutional animal 
care committee’s guidelines.  
B.1.3. Genomic DNA isolation and PCR amplification. Genomic DNA was isolated 
using proteinase K method. Briefly, tail tips were digested in 0.6 ml of genomic DNA 
isolation buffer (20mM Tris, pH-7.5, 50mM EDTA, 100mM NaCl, 0.5% SDS, freshly 
added 500ug/ml proteinase K) at 42 degrees overnight. After incubation, added 240ul tail 
salts (4.21 M NaCl, 0.63M KCl, 10mM Tris, pH-8.0), vortexed, incubated at 4 degrees 
for 30 minutes. Tubes were centrifuged at 13krmp for 10 minutes and supernatant 
removed into a different tube, followed by adding 1X 100% ethanol. DNA was then 
pelleted at maximum speed for 2 minutes, washed with 80% ethanol, followed by 
suspension in 100ul TE buffer. 50 ng genomic DNA was used as a template for PCR 
amplification using primer sequences indicated in Fig. B.1. PCR conditions used were 
98°C 5’, followed by 25 cycles of 98°C 15’’, 62°C 15’’, 72°C 15’’.  
B.1.4. Surveyor Assay. Procedure was performed following the manufacturer’s protocol. 
Briefly, 400ng PCR amplicons in a 7.5 μl reaction were denatured and reannealed using 
PCR program as described in manual. After hybridization reaction was over, added 0.25 
μl nuclease and 1 μl enhancer followed by incubation at 37°C 60’. Reaction products 
were then run on a 2% agarose gel.  
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B.2. Results and Discussion 
B.2.1. Screening for best TALEN pair. Five different TALEN pairs were designed to 
target exon 3 of the murine XPLN gene. Exon 3 was selected for targeting since it is the 
earliest exon in the XPLN coding sequence that was shared by all alternate transcripts of 
XPLN, except transcript 1 and 10 that lack the functional part (first 125 amino acids) of 
the XPLN protein altogether. Their sequences and binding sites in XPLN gene are 
depicted in Fig. B.1.   
 As shown in Fig. B.2, Surveyor enzyme consistently showed cutting for genomic 
DNA isolated from TALEN pair 2 transfected C2C12 cells. Hence, TALEN pair 2 was 
chosen for in vitro transcription and embryo injection.  
  
B.2.2. Identification of F0 mutant founder mice. 10 founder females gave birth to a 
total of 44 pups. Genomic DNA was isolated from the tail tips of these pups upon 
weaning followed by PCR amplification and surveyor assay. As shown in Fig. B.3, DNA 
from 9 pups generated cleavage bands following surveyor assay, as indicated by star. 
These pups could be potentially heterozygous for XPLN mutated DNA.  
Additionally, genomic DNA from pup #5, #36, #37 showed strong PCR products 
of size ~310bp, 250bp, and 290bp, besides the normal 400bp WT parental band, as 
indicated by arrowheads. These bands were gel purified followed by sequencing. Results 
from sequencing confirmed deletion of varying number of nucleotides ranging from 8-9 
nucleotides (Fig. B.4). 
Pups #5, 36: deletion of 8 nucleotides from 242-249 (AAGCGCTT) 
Pup #37: deletion of 9 nucleotides from 238-245 (ATTAAAGCG)  
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B.3. Figures 
GGGGGGTGGGGAAGGGGGGGTAGGATCCCTACCTTTCTGTCACCCACTGCTTCAGTGTGC 
CTCCTCCGTCTTTTCTCTTTCATGGCTCCCCAGCCAGATCACCTGTGCAGATCCTGGGGC 
ACCGTTCACGGGTCTACAGATCACCCTGTCGCCTGCAAGTCTCAGAGCAGGATGGATGTG 
ATGTTGTGGCAGACATCTGTAAGATTGGTCTTGACACTGTCCTCTTTTTTTTTTTTTTTT 
CTTTTATACAGGAACCTAGTAACAAAAGGGTCAAACCCCTTTCCAGAGTCACATCGCTAG 
CAAACCTCATTCCACCTGTGAAGACCACACCATTAAAGCGCTTCAGCCAGACCTTGCAGG 
TAAGGGAACGTGGGCTTGGGCTTGGGCTTGCAGAGAGCCATGCTGTGCTCATGCACCTAG 
CATCTCTGTGGGTCTCCGGTGGAGCTGAATCACCACTTGCTACTGTAGAAGAGTGCACAG 
GTGAAGGGGAATAAAAGGACGAGAAATGTGTGCACGCCACAACCCCGGGTCAGGCAGGGT 
CAGGGCCACTTCTGATAGTTCATAGTTGTATGTCTATGTCATAGGTCCTATCCGAGTGTA 
 
ARHGEF3 Exon 3 sequence 
Primer Pair used for amplification 
 
GGGGGGTGGGGAAGGGGGGGTAGGATCCCTACCTTTCTGTCACCCACTGCTTCAGTGTGC 
CTCCTCCGTCTTTTCTCTTTCATGGCTCCCCAGCCAGATCACCTGTGCAGATCCTGGGGC 
ACCGTTCACGGGTCTACAGATCACCCTGTCGCCTGCAAGTCTCAGAGCAGGATGGATGTG 
ATGTTGTGGCAGACATCTGTAAGATTGGTCTTGACACTGTCCTCTTTTTTTTTTTTTTTT 
CTTTTATACAGGAACCTAGTAACAAAAGGGTCAAACCCCTTTCCAGAGTCACATCGCTAG 
CAAACCTCATTCCACCTGTGAAGACCACACCATTAAAGCGCTTCAGCCAGACCTTGCAGG 
TAAGGGAACGTGGGCTTGGGCTTGGGCTTGCAGAGAGCCATGCTGTGCTCATGCACCTAG 
CATCTCTGTGGGTCTCCGGTGGAGCTGAATCACCACTTGCTACTGTAGAAGAGTGCACAG 
GTGAAGGGGAATAAAAGGACGAGAAATGTGTGCACGCCACAACCCCGGGTCAGGCAGGGT 
CAGGGCCACTTCTGATAGTTCATAGTTGTATGTCTATGTCATAGGTCCTATCCGAGTGTA 
 
ARHGEF3 Exon 3 sequence 
TALEN 1 LEFT SEQUENCE: T-TTCCAGAGTCACATCGCTAG 
TALEN 1 RIGHT SEQUENCE: T- CTGGCTGAAGCGCTTTAAT 	  
GGGGGGTGGGGAAGGGGGGGTAGGATCCCTACCTTTCTGTCACCCACTGCTTCAGTGTGC 
CTCCTCCGTCTTTTCTCTTTCATGGCTCCCCAGCCAGATCACCTGTGCAGATCCTGGGGC 
ACCGTTCACGGGTCTACAGATCACCCTGTCGCCTGCAAGTCTCAGAGCAGGATGGATGTG 
ATGTTGTGGCAGACATCTGTAAGATTGGTCTTGACACTGTCCTCTTTTTTTTTTTTTTTT 
CTTTTATACAGGAACCTAGTAACAAAAGGGTCAAACCCCTTTCCAGAGTCACATCGCTAG 
CAAACCTCATTCCACCTGTGAAGACCACACCATTAAAGCGCTTCAGCCAGACCTTGCAGG 
TAAGGGAACGTGGGCTTGGGCTTGGGCTTGCAGAGAGCCATGCTGTGCTCATGCACCTAG 
CATCTCTGTGGGTCTCCGGTGGAGCTGAATCACCACTTGCTACTGTAGAAGAGTGCACAG 
GTGAAGGGGAATAAAAGGACGAGAAATGTGTGCACGCCACAACCCCGGGTCAGGCAGGGT 
CAGGGCCACTTCTGATAGTTCATAGTTGTATGTCTATGTCATAGGTCCTATCCGAGTGTA 
 
ARHGEF3 Exon 3 sequence 
TALEN 2 LEFT SEQUENCE: T-CCACCTGTGAAGACCACAC 
TALEN 2 RIGHT SEQUENCE: T-CCCTTACCTGCAAGGTCT 	  
GGGGGGTGGGGAAGGGGGGGTAGGATCCCTACCTTTCTGTCACCCACTGCTTCAGTGTGC 
CTCCTCCGTCTTTTCTCTTTCATGGCTCCCCAGCCAGATCACCTGTGCAGATCCTGGGGC 
ACCGTTCACGGGTCTACAGATCACCCTGTCGCCTGCAAGTCTCAGAGCAGGATGGATGTG 
ATGTTGTGGCAGACATCTGTAAGATTGGTCTTGACACTGTCCTCTTTTTTTTTTTTTTTT 
CTTTTATACAGGAACCTAGTAACAAAAGGGTCAAACCCCTTTCCAGAGTCACATCGCTAG 
CAAACCTCATTCCACCTGTGAAGACCACACCATTAAAGCGCTTCAGCCAGACCTTGCAGG 
TAAGGGAACGTGGGCTTGGGCTTGGGCTTGCAGAGAGCCATGCTGTGCTCATGCACCTAG 
CATCTCTGTGGGTCTCCGGTGGAGCTGAATCACCACTTGCTACTGTAGAAGAGTGCACAG 
GTGAAGGGGAATAAAAGGACGAGAAATGTGTGCACGCCACAACCCCGGGTCAGGCAGGGT 
CAGGGCCACTTCTGATAGTTCATAGTTGTATGTCTATGTCATAGGTCCTATCCGAGTGTA 
 
ARHGEF3 Exon 3 sequence 
TALEN 3 LEFT SEQUENCE: T-CAAACCCCTTTCCAGAG 
TALEN 3 RIGHT SEQUENCE: T-GTGGTCTTCACAGGTG 
 
Fig. B.1. Sequences of 5 TALEN pairs and their binding sites in XPLN gene. 
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Fig. B.1. (Continued) 
 
GGGGGGTGGGGAAGGGGGGGTAGGATCCCTACCTTTCTGTCACCCACTGCTTCAGTGTGC 
CTCCTCCGTCTTTTCTCTTTCATGGCTCCCCAGCCAGATCACCTGTGCAGATCCTGGGGC 
ACCGTTCACGGGTCTACAGATCACCCTGTCGCCTGCAAGTCTCAGAGCAGGATGGATGTG 
ATGTTGTGGCAGACATCTGTAAGATTGGTCTTGACACTGTCCTCTTTTTTTTTTTTTTTT 
CTTTTATACAGGAACCTAGTAACAAAAGGGTCAAACCCCTTTCCAGAGTCACATCGCTAG 
CAAACCTCATTCCACCTGTGAAGACCACACCATTAAAGCGCTTCAGCCAGACCTTGCAGG 
TAAGGGAACGTGGGCTTGGGCTTGGGCTTGCAGAGAGCCATGCTGTGCTCATGCACCTAG 
CATCTCTGTGGGTCTCCGGTGGAGCTGAATCACCACTTGCTACTGTAGAAGAGTGCACAG 
GTGAAGGGGAATAAAAGGACGAGAAATGTGTGCACGCCACAACCCCGGGTCAGGCAGGGT 
CAGGGCCACTTCTGATAGTTCATAGTTGTATGTCTATGTCATAGGTCCTATCCGAGTGTA 
 
ARHGEF3 Exon 3 sequence 
TALEN 4 LEFT SEQUENCE: T-CATTCCACCTGTGAAGAC 
TALEN 4 RIGHT SEQUENCE: T-CCCTTACCTGCAAGGTCT 
 
 
GGGGGGTGGGGAAGGGGGGGTAGGATCCCTACCTTTCTGTCACCCACTGCTTCAGTGTGC 
CTCCTCCGTCTTTTCTCTTTCATGGCTCCCCAGCCAGATCACCTGTGCAGATCCTGGGGC 
ACCGTTCACGGGTCTACAGATCACCCTGTCGCCTGCAAGTCTCAGAGCAGGATGGATGTG 
ATGTTGTGGCAGACATCTGTAAGATTGGTCTTGACACTGTCCTCTTTTTTTTTTTTTTTT 
CTTTTATACAGGAACCTAGTAACAAAAGGGTCAAACCCCTTTCCAGAGTCACATCGCTAG 
CAAACCTCATTCCACCTGTGAAGACCACACCATTAAAGCGCTTCAGCCAGACCTTGCAGG 
TAAGGGAACGTGGGCTTGGGCTTGGGCTTGCAGAGAGCCATGCTGTGCTCATGCACCTAG 
CATCTCTGTGGGTCTCCGGTGGAGCTGAATCACCACTTGCTACTGTAGAAGAGTGCACAG 
GTGAAGGGGAATAAAAGGACGAGAAATGTGTGCACGCCACAACCCCGGGTCAGGCAGGGT 
CAGGGCCACTTCTGATAGTTCATAGTTGTATGTCTATGTCATAGGTCCTATCCGAGTGTA 
 
ARHGEF3 Exon 3 sequence 
TALEN 5 LEFT SEQUENCE: T-ATACAGGAACCTAGTAACAA 
TALEN 5 RIGHT SEQUENCE: T-TTGCTAGCGATGTGACTCT 
 
Fig. B.1. Sequences of 5 TALEN pairs and their binding sites in XPLN gene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
	   105	  
 
 
Fig. B.2. Gel showing the Surveyor nuclease result from five XPLN TALEN pairs. 
Lane 1: DNA ladder. Lanes 2,4: positive control for surveyor assay. Lane 3,5: negative 
control for surveyor assay. Lane 6-10: cells transfected with a plasmid carrying XPLN 
TALEN pair (number as indicated) Lane 11: control from un-transfected cells The two 
lower bands as indicated by stars are Surveyor-cleaved DNA products. The arrowheads 
indicate bands generated from positive control.  
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Fig. B.3. Gels showing the Surveyor nuclease result from 44 F0 pups. Each gel has 
lane 1 as marker followed by surveyor nuclease result from the pups (numbers as 
indicated above). Last gel contains WT DNA with (+) or without surveyor enzyme (-) as 
control. The arrowheads indicate strong PCR amplicons generated by pups #5, #36, and 
#37 that were sent for sequencing. Pups whose genomic DNA reliably generate cleavage 
products following surveyor assay are indicated by stars underneath.  
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